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Inactivation of the tumor suppressor phosphatase and tensin liomolog deleted on
chromosome 10 (PTEN) is heavily implicated in the tumorigenesis of prostate cancer.
Conversely, the upregulation of the chemokine (CXC) receptor 4 (CXCR4) is associated
with prostate cancer progression and metastasis. The inactivation of functional PTEN is
typically due to genetic and epigenetic modulations, as well as active site oxidation by
reactive oxygen species (ROS); likewise ROS upregulates CXCR4 expression.
Furthermore, the pathways of CXCR4 and PTEN converge, leading to the
promotion and regulation of turnorigenesis, respectively. Based on these observation we
hypothesized that, PTEN inhibits CXCR4-mediated functions in prostate cancer cells.
This hypothesis was investigated through the following aims: (1) To determine whether
PTEN inhibits CXCR4-mediated functions in prostate cancer cells and, (2) To investigate
a mechanism by which PTEN function is lost, and CXCR4 function is gained in prostate
cancer cells.
Upon screening advanced metastatic prostate cancer cell lines for PTEN,
identified a loss of expression in PC3 and LNCaP cells, whereas DU145 expressed
wildtype PTEN. All three cell lines were positive for surface expression of CXCR4.
Reconstitution of PTEN induced a mesenchymal to epithelial-like morphological change
and inhibited CXCR4-mediated migration and proliferation in PC3 cells.
Downregulation of PTEN by siRNA enhanced the CXCR4-mediated migratory behavior
of DU 145 cells. By western blot analysis, we observed that PTEN inhibited basal Protein
Kinase B (AKT) phosphorylation, but not extracellular signal-regulated kinase 1/2
(ERKI/2) phosphorylation in PTEN expressing cells. Upon CXCR4 stimulation, PTEN
inhibited ERKI/2 phosphorylation, but not phosphorylation of AKT. The CXCR4-
mediated migration of PC3 cells was through the ERKI/2 pathway, as confirmed by
chemical inhibitors. Based on these studies, we suggest that loss of PTEN permits
CXCR4-mediated functions in prostate cancer cells, through the ERKI/2 pathway.
We also observed that ROS increased expression of phosphorylated AKT (p
AKT) and phosphorylated ERKI/2 (p-ERK1/2) in DU145 and 22Rv1 prostate cancer cell
lines, which was abrogated by the ROS scavenger N-acetyl cysteine (NAC). This study
showed that PTEN, was oxidized by ROS accumulation. The oxidized form of PTEN
became catalytically inactive, although the expression levels of PTEN remained
consistent. Additionally, the ROS-mediated inactivation of PTEN enhanced hypoxia
inducible factor lcL (HIF1CL) and CXCR4 expression, and invasion and migration of
DU145 cells, in a CXCR4-dependent manner. Interestingly, at the same ROS
concentration, 22Rv1 cells did not display mitogenic effects. HIFlo expression
decreased in 22Rv1 cells and the cells became apoptotic, despite the increases in AKT
and ERKI/2. Taken together, antagonizing CXCR4 and downstream signaling cascades
may provide an efficient approach for treating patients with advanced prostate cancer.
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Prostate cancer is the most commonly diagnosed disease and second leading
cause of deaths among men in the United States, where about 240,890 new cases of
prostate cancer were diagnosed and 33,720 men died in 2011 from this disease.1 It is
estimated that 90% of new cases of prostate cancer are expected to be diagnosed at an
early stage, for which the 5-year relative survival approaches 100% due to better
treatments and methods of detection.2 Despite these advances, prostate cancer still
accounts for approximately 10% of cancer-related deaths in men, mainly because some
prostate tumors have become resistant to therapeutic treatments. For this reason new and
effective therapies are warranted to alleviate this problem.
The tumorigenesis of prostate cancer is facilitated by several factors, these are (I)
diet, (2) environment, (3) socioeconomic, (4) genetics and (5) inflammation.3 The
genetic and molecular causes of prostate cancer have been deeply studied over the past
decades, resulting in the development of potent therapeutic agents. Despite these
advancements, the incident and mortality rate of prostate cancer remains relatively high
compared to all cancer type. It has been recognized that cancer resistance is due to
changes in the genetic and molecular alterations.4 Notably, initial treatment of prostate
cancer have proven effective; however, continuous treatment has led to prostate cancer
resistance. Therefore, further studies are required to understand the evolving genetic and
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molecular mechanisms that contribute to prostate cancer development and progression,
which will aid in the development of new and effective therapeutics.
It is generally accepted that prostate cancer development and progression is
dependent upon increasing levels of androgens, which stimulate the growth, survival and
function of cells that express the androgen receptor. During the early stages of prostate
cancer, hormone deprivation therapy has proven to be effective. However, advanced
prostate tumors grow accustomed to androgen depletion, circumvent restraints on growth
and movement, and eventually develop metastatic colonies in the bones and other distal
organs. Progression to androgen-insensitivity is mediated largely by androgen receptor
(AR); however, this process is distinct from metastatic progression, where tumor
suppressors fail to regulate signals that influence cell proliferation, adhesion, anchorage
and movement.5
Loss of tumor suppressor genes leads to tumorigenesis of many cancer models
including prostate cancer. Typically, tumor suppressor genes are inactivated through
several molecular mechanisms such as genetic mutations, epigenetic modifications.
Additionally, tumor suppressors, such as PTEN may also be inactivated by ROS to
enhance cancer progression. ROS are oxygen containing reactive radicals that play a role
in regulating various signal transduction pathways associated with cell survival.
Furthermore, studies have shown that the accumulation of ROS, whether endogenously
or exogenously, leads to tumor development and progression in various cancers,
including prostate cancer cells.6 Interestingly, a significant portion of ROS is derived
from the tumor microenvironment, immune cells and stromal cells, while endogenous
ROS production are due to malfunction of redox homeostasis. Due to the mitogenic
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nature of ROS, the removal with antioxidant compounds are currently as a
chemotherapeutic agent in cancer treatment. Interestingly, overwhelming levels of ROS
are associated with activating apoptosis in malignant cells; thus, induction of ROS has
also been used in cancer therapy.
It is has been demonstrated that ROS functions by regulating tumor suppressors
and oncogene, either through gene expression or post-translational modification. For
instance, studies have shown that ROS inactivates the tumor suppressor PTEN, while
inducing the expression the oncogenic molecules such as ERK1/2, HlFlci, AKT, myc and
CXCR4.7’8
CXCR4 is a member of the chemokine receptor, which are G-protein coupled
receptors (GPCR). In the context of prostate cancer, Wallace et al. have demonstrated
that CXCR4 expression contributes to advanced metastatic stages of prostate cancer.9
CXCR4 and its ligand, SDF1a also known as CXCL12, play a crucial role in targeting
solid tumor metastases to sites outside of the primary tumor and have become a potential
target for therapeutic intervention in malignancies that metastasize.10 A study done by
Akashi et al. revealed that CXCR4 expression was higher in malignant prostate tumors
than in their normal healthy counterparts, suggesting that its expression level correlated
with increased metastasis-associated mortality.’1 Positive expression of CXCR4 has
become a superior predictor of tumor aggressiveness, poor prognosis and prostate cancer
bone metastasis.12 Durr et al. have reported that CXCR4 is involved in the recruitment of
immune cells to the tumor microenvironment suggesting a cross talk between CXCR4
and the microenvironment.13 Additionally, CXCR4 is heavily implicated in the
metastasis of various cancer types such as breast, lung, brain and prostate.’4 In cancer
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metastasis, CXCR4 has been shown to be involved in: (i) cell motility; (ii) adhesion; (iii)
secretion of matrix metalloproteinases (MMP5); (iv) angiogenesis and (v) the activation
of metastatic associated signaling pathways (G-proteins, PI3K/AKT, JAK/STAT, Src
kinase and HER2).’’7
In prostate cancer, the PI3K!AKT and ERKI/2 are heavily associated with the
tumor development and progression.’8’19 These pathways regulate various cellular
processes that control cell survival, proliferation and differentiation. In cancer cells,
these pathways are dysregulated by upregulation of activator and inhibition of tumor
suppressor molecules. One molecule that classically regulates the PI3K/AKT and
ERKI/2 pathways is the tumor suppressor PTEN. In prostate cancer cells, loss of PTEN
is implicated in malignant transformation.20 Typically, loss of PTEN is driven by
genomic and epigenetic modifications; however, emerging studies indicate that ROS
accumulation also inactivates PTEN function.21 In prostate cancer, inactivation of PTEN
appears to act as a permissive event for uncontrolled cell proliferation, invasion and
metastasis.17 Although PTEN haploinsufficiency is strongly correlated with the
conversion of a high-grade prostatic intraepithelial neoplasia (PIN) to an invasive
adenocarcinoma, the underlying mechanisms permitting ensuing invasion and metastasis
are poorly understood.22 PTEN functions as a dual-specificity lipid and protein
phosphatase that inhibits cell proliferation, survival and growth predominantly through
dephosphorylation of phosphatidyl inositol 3,4,5-trisphosphate (PIP3), thus antagonizing
phosphatidyl inositol 3-kinase (P13 K)/Protein Kinase B (AKT)—mediated signaling
events.23 By converting PIP3 into phosphatidylinositol 4,5-bisphosphate (PIP2), PTEN
negatively regulates PI3K-AKT signaling and subsequently downstream cellular
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functions such as apoptosis, protein synthesis, metabolism, cell cycle, proliferation,
invasion, metastasis, angiogenesis, and overall survival.24 Regulating the
PI3K/AKT/mTOR signaling pathway has been shown to be pivotal to prostate cancer
proliferation, and the pathogenesis of an advanced disease.2
Independently, PTEN and CXCR4 have been noted for their involvement in
prostate cancer invasion, metastasis and progression. To date, one link has been
established between CXCR4 and PTEN in inflammatory chemotaxis, whereby PTEN
inhibited movement of Jurkat cells stimulated with SDF1a.26 In non-small cell lung
cancer, Phillips et al. observed that PTEN blocked hypoxia-induced expression of
CXCR4.27 Likewise in prostate cancer, Carver et al. observed a correlation in expression
between PTEN and CXCR4; however, neither study reported a functional relationship.28
Considering that both PTEN and CXCR4 converge at the similar signaling pathways, it is
plausible to suggest that PTEN is involved in regulating CXCR4 function. Loss of PTEN
is typically associated with tumor development and progression. Currently, PTEN is
inactivated by genetic modifications and epigenetic alterations. However, mounting
evidence has shown that ROS is also associated with inactivating PTEN by forming a
disulfide bond within the active site, rendering it catalytically inactive.
It has been established that ROS are produced by the tumor microenvironment
and cellular metabolic processes. The accumulation of ROS typically regulates cell
survival, proliferation and migration in cancer cells by functioning as a second messenger
in intracellular signal transduction; however, excessive amounts of ROS in cells result in
deleterious effects, such as genotoxicity and cell death. Under physiologic conditions,
ROS homeostasis is maintained by various neutralizing enzymes, such as catalase and
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superoxide dismutase. An imbalance in ROS homeostasis is associated with prostate
tumorigenesis by activating pro-cancer signaling pathways and inactivating tumor
suppressor genes. Furthermore, ROS has been linked to cell survival through activation
of PI3KJAKT and ERKI/2 pathways.
Collectively, ROS accumulation may play a role in regulating PTEN function and
ultimately CXCR4-mediated metastatic function. Considering that PTEN and CXCR4
have converging pathways, at the PI3K/AKT, and ROS may regulate PTEN; this study
investigates the role of ROS on CXCR4-mediated functions in prostate cancer cells. The
effect of the tumor microenvironment on CXCR4 may be mediated by the inhibitory
function of ROS on PTEN. Therefore, the hypotheses for this study are:
I. PTEN expression regulates CXCR4-mediated metastatic function
2. ROS regulates CXCR4 expression and function by inhibiting PTEN




2.1 The Human Prostate Gland
The human prostate gland is a small, muscular, round organ about 4 cm in
diameter, which encircles the proximal portion of the urethra as it leaves the urinary
bladder (Figure lA).29 Although the adult prostate lacks discernible lobular structure, it
is generally accepted that the prostate has a zonal architecture, corresponding to central,
periurethral transition, and peripheral zones, together with an anterior fibromuscular
stroma (Figure IB).3° The function of the prostate gland is to produce prostatic fluid, a
slightly alkaline solution that nourishes and protects semen.29 Dysfunction of the prostate
confers various diseases such as prostatitis, benign prostatic hyperplasia (BPI-l), a
common nonmalignant condition found in older men, and prostate cancer. In fact, the
outermost peripheral zone occupies the most volume, and typically harbors the majority
of prostate carcinomas, while BPH arises from the transition zone.30
2.2 Prostate Cancer Development and Progression
Much experimental evidence has concluded that cancer is due to a dysregulation
of specific molecular and genetic pathways that are involved in regulating cell survival
and proliferation.31 Furthermore, other theories suggest that cancer may originate from
stem cells, this is based on the observations that cancer cells can self-renew and are
7





Figure 1: (A) Schematic showing the location of the prostate gland relative to the
bladder, anus and penis. (B) Schematic illustration of the anatomy of the prostate.’
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more that 1% of all human genes are associated with malignant transformation, of which
90% exhibit somatic mutations.3’ In prostate cancer, genomic alterations play a
significant role in promoting tumor developmen, through the inactivation of tumor
suppressor genes such as Rb, p53 and PTEN, and/or activation oncogenes such as Myc,
Raf and src.30 Furthermore, these genomic alterations may be in the form of DNA
mutations and chrornosomal rearrangements. For example, in prostate cancer, several







including gains at 8q and losses at 3p, 8p, lOq and 17p.32 In addition to genomic
alterations prostate cancer development and progression are also due to several other
factors including epigenetic modifications, inflammation and oxidative stress.
Interestingly, these factors facilitate prostate cancer development and progression by
operating individually or cooperatively.
In the developmental progression of prostate cancer, prostatic intraepithelial
neoplasia (PIN) is a known precursor, which is characterized by the appearance of
luminal epithelial hyperplasia, a decrease in basal cells, and enlargement of nuclei; while
advanced PIN typically expresses cellular proliferation markers.33 The continuous
exposure of PIN to the host inflammatory cells, oxidative stress, mitogenic factors (e.g
growth factors and cytokines) and microenvironment promote prostate cancer
development, which is pathologically classified as adenocarcinoma.3°Together host
inflammatory cells and cells surrounding tumor cells are defined as the tumor
microenvironment, which is a complex, multi-cellular environment
2.3 The Role of Tumor Microenvironment in Cancer Metastasis
Under normal physiologic conditions, the cellular microenvironment is able to
suppress malignant cell proliferation. However, the microenvironmental interactions
between tumor and stroma are crucial in tumorigenesis and cancer progression of various
cancer types including breast, lungs and prostate cancers.34 This tumor
microenvironment consists of various cell types such as lymphocytes, leukocytes,
fibroblast cells and malignant cells that are embedded within the extracellular matrix and
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interstitial fluid. This gives rise to a complex network of cross interaction between non
malignant cells and malignant celIs.3
The establishment of the tumor microenvironment begins with the accumulated
mutations in epithelial cells which leads to dysregulations of cellular processes, such as
cell proliferation. Consequently, these dysregulation may also result in signals to recruit
various immune cells, such as leukocytes.36 These signals that are secreted are cytokines
and chemokines to attract immune cells from malignant cells to facilitate tumor
development and progression.37 Furthermore, fibroblast cells also promote tumor
development and spread, mediated through the secretion of growth factors as well as
chemokines.38 Taken together, both immune and fibroblast cells influence tumor cells to
progress to an advanced metastatic form.
It is well established that host inflammatory response suppresses tumor
development and progression. Conversely, several studies have indicated that
macrophage activation can kill tumor cells, however, this function may be lost due to
resistant tumor cells.39 Resistance to immunogenicity is usually due to an accumulation
of DNA alterations and consequential dysregulation of cell death pathway.4°The
exposure of inflammatory cells to tissues results in promoting tumor progression by
secreting growth factors, cytokines, chemokines and ROS. Continuous exposure to these
molecules leads to progressive DNA damage, loss of DNA repair mechanism, loss of cell
cycle control and activation of cell survival pathways, all of which are required for
neoplastic transformation.4°Immune cells may also infiltrate tumor mass and
consequently promote tumor progression, survival, angiogenesis and metastasis.41
Typically, T-cells neutrophils, dendritic cells, macrophages, eosinophils and mast cells
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infiltrate tumors and become part of the tumor microenvironment.42 All of these cells
are capable of producing various cytokines, growth factors, cytotoxic mediators including
ROS. proteases, and MMPs to enhance tumor development and progression.4°
In addition to immune cells, fibroblast cells are also found in the tumor
microenvironment, and have been shown to influence tumorigenesis. In normal tissue,
fibroblasts cells are the predominant cell type in the stroma and are the primary producers
of the fibrillar-ECM by depositing collogen, fibronectin and laminin.43 Additionally,
fibroblast are also involved in secreting various chemokines, cytokines and growth
factors particularly response to tissue injury and inflammation.43 During these responses,
fibroblasts activation are involved in a dynamic crosstalk with immune cells through
direct contact. This crosstalk is mediated via adhesion molecules and respond to various
factors secreted by the immune cells or epithelial cells. Fibroblasts found within the
tumor microenvironment have acquired constitutively activated phenotype and are
designated as cancer-associated fibroblasts.
Cancer-associated fibroblasts are among the most abundant cell types in the
microenvironment of solid tumors, being particularly prominent in breast, colon and
prostate cancers.44 Mounting evidence has demonstrated that cancer-associated
fibroblasts contribute to tumor development and progression by secreting various
chemokines and growth factors such as EGF, HGF and TGFf3. All these factors are
critical in cells and play a critical role in tumor development and progression.
Taken together, the tumor microenvironment is a complex collection of immune
cells, fibroblast cells, non-malignant cells and cancer cells. The continuous interaction of
these cells, whether directly or indirectly, influences tumor cells to progress to an
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advanced stage. Hence, it is critical to investigate this intricate network of
communication so as to develop better therapy options.
2.4 Chemokine (CXC motif) Receptor 4
The chemokine network consists of approximately 50 chemokine ligands and 19
chemokine receptors. These receptors are G-protein coupled receptors (GPCR) that are
divided into 4 groups (CXC, CX3, CC and C) according to the first two and highly
conserved cysteines of the N-terminus sequence.45 Chemokine receptors are activated by
chemokine ligands, which bind to several different chemokines receptors, or one
chemokine receptor exclusively. One such signaling relationship is the CXCR4/SDFIcx
(also known as CXCLI2) axis.
Located at chromosome 2q21, the CXCR4 gene is a 352 amino acid G-protein
coupled receptor that is expressed in immune cells.46 However, loss of the CXCR4 gene
in mice resulted in impaired embryologic, immune, circulatory and central nervous
system development, suggesting an important role for CXCR4 in organogenesis.47’8
Classically, CXCR4 has been known to regulate chemotactic cell motility in neutrophils,
myeloid cells and lymphocytes.46’9 For instance, several tissues such as liver, kidney
and central nervous system responded to tissue damage or inflammation by secreting the
ligand SDFIa, which recruits CXCR4 positive progenitor cells to the inflamed site.50
Recent genetic studies have shown that CXCR4 localized at the nucleus of
various cell models such as renal cell carcinoma (RCC).51 To corroborate this finding,
Wang et al. discovered a nuclear localization sequence (NLS) between amino acids 90-
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170 on the CXCR4 gene.52 However, whether a nuclear localized CXCR4 participates in
signaling or nuclear functions remain unclear.
The activation of CXCR4 has been shown to play a critical role in normal
physiologic functions, such as (i) adhesion, (ii) chemotactic response, (iii) secretion of
matrix metalloproteases (MMP), and (iv)angiogenic factors.53’4 In hematopoietic cells,
CXCR4/ SDFIcx promoted adhesion by activating various molecules such as integrins,
LFA-I (lymphocyte function associated antigen-I), VLA-4 (very late activation antigen-
4) and VLA-5 The stimulation of CXCR4 activated NF-KB, which promoted the
secretion of various molecules, such as MMP-2, MMP-9 and VEGF. In malignant cells
these molecules played a critical role in promoting invasion and angiogenesis.53’6
CXCR4-mediated migration has been shown to involve the activation of
phosphoinositide-3 kinase (P13K) and protein kinase B/AKT (AKT) pathway. PI3K/AKT
activation resulted in Rac stimulation, which promoted actin polymerization in
lamellipodia formation on the leading edge of the cell.57
In addition to P13 K, CXCR4 has been shown to activate several other pathways,
such as ERKI/2, Jak/Stat, and G-proteins. Studies have shown that CXCR4 induced
phosphorylation of mitogen-activated protein kinases (MAPK), and subsequently
activated extracellular signal-regulated kinases I (ERK-1) and 2 (ERK-2) in human
Jurkat T-cells.58 The MAPK/ERK pathway has been shown to regulate cell proliferation
and migration.59For this reason, the increased activity of the ERKI/2 pathway has been
frequently observed in a variety of malignant cells, such as breast cancer and prostate
cancer.60 The activation of the JAK/STAT pathway is due to the transient association of
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CXCR4 with JAK2 and JAK3, which leads to the nuclear translocation of various STAT
transcription factors.61
Another signaling pathway that is regulated by CXCR4 is the PI3K/AKT
pathway. Following ligand binding, CXCR4 liberates G and Gp, which activates the
PI3K/AKT pathway (Figure The P13K protein is a plasma membrane associated
enzyme that phosphorylates the 3’ hydroxyl group of the inositol ring of
Figure 2: Schematic showing the signal transduction pathways that are regulated upon
CXCR4 activation
phosphatidylinositol, converting phosphatidylinositol 4, 5-phosphatase (PIP2) to
phosphatidylinositol 3, 4, 5-phosphatase (PIP3).18 PIP3 recruits AKT to the plasma
membrane to mediate its activation. P13K can alternatively phosphorylate phospholipid
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dependent kinase I (PDKI). which then activates AKT by phosphorylation. Moreover,
AKT activates downstream targets necessary for cell survival, metastasis anti-apoptosis,
and inhibits anti- tumorigenic molecules such as BAD (pro-apoptosis), procaspase-9
(pro-apoptosis), GSK and tumor suppressors, such as BRCAI. Interestingly, the
PI3K/AKT pathway has been shown to be up regulated in advanced metastatic cancers,
including prostate cancer.15 Because CXCR4 regulates a variety of signaling pathways
involved in cell proliferation, cell survival, cell invasion and cell migration, it has been
shown to play a critical role in cancer progression.
2.5 The Role of CXCR4 in Prostate Cancer
Dysregulation of CXCR4 is associated with the pathogenesis of various diseases.
For instance, CXCR4 is a known cofactor that mediates HIV-l fusion and entry into T
cells, ultimately resulting in AIDS progression.62 In addition to promoting l-IIV infection,
CXCR4 has also been implicated in malignant transformation of several cancer models,
where CXCR4 is the most expressed chemokine receptor detected in 23 different types of
cancers of various origins, including prostate cancer.63’4
The role of CXCR4 in prostate cancer metastasis was first observed by Taichrnan
et al, who showed that CXCR4 facilitated prostate cancer metastasis to the bone.12 At the
bone microenvironment, SDFIo was constitutively expressed by osetoblasts, fibroblasts,
and endothelial cells. thus providing a chemoattraction for CXCR4-expressing cells,
including prostate cancer cells. This model of chemoattraction facilitated metastasis has
been established in several models of cancers including, breast, melanoma, lung and
pancreatic cancer.60’ CXCR4-mediated metastatic events correlate with activation of
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various signaling pathways such as the PI3K/AKT, MAPK and JAK/STAT pathways
(Figure 2). However, studies have shown that CXCR4 mediates metastatic events by
differentially activating these pathways in various cancer types. For instance, in prostate
cancer, CXCR4 preferentially activates the PI3K/AKT pathway; however, emerging
studies have suggested that the MAPK pathway is also activated. Recent reports suggest
that activated AKT negatively regulates the ERK pathway by inhibiting the RAF
oncoprotein.66
CXCR4-mediated activation of PI3K/AKT has been shown to activate
downstream targets necessary for cell survival, cell motility, anti-apoptosis and stimulate
the expression of pro-tumorigenic molecules (Figure 2). Activation of AKT by CXCR4
facilitates invasion and overexpression of MMP-1 and MMP-13 enzymes to degrade the
extracellular matrix (ECM).67 Degradation of the ECM by MMP-l and MMP-13
facilitated prostate cancer cell invasion by rearranging cytoskeletal proteins to form
lamellipodia and pseudopodia in a Rac dependent manner.68 Furthermore, the
stimulation of CXCR4 resulted in an increase in adhesion of PC3 (prostate cancer cells)
to endothelial cells.69 Adhesion promoted by CXCR4 in prostate cancer was mediated
via the expression of cz.5 and integrins.7°Collectively, CXCR4 has been shown to
mediate metastatic events in prostate cancer cells. However, the underlying mechanisms
by which CXCR4 coordinates metastasis in prostate cancer are not fully understood.
2.6 Phosphatase and Tensin homolog deleted on chromosome 10q23 (PTEN)
Tumorigenesis is the result of mutations or epigenetic modifications in three
types of genes: (I) oncogenes, (ii) caretaker genes and (iii) tumor suppressors. Mutations
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in proto-oncogenes result in the up-regulation of oncogenes, which promote cell
proliferation and survival. Moreover, mutations or epigenetic silencing in caretaker or
tumor suppressor genes are associated with unrestrained cell proliferation. Tumor
suppressor proteins inhibit cell growth and survival by regulating a variety of cellular
functions, including cell cycle, apoptosis, DNA repair, signal transduction, and cell
adhesion. Therefore, inactivation of tumor suppressor genes, usually by genetic
instability, chromosomal deletions and hypermethylation promotes malignant cell growth
and survival. One frequently inactivated tumor suppressor found in a variety of human
cancers, including prostate cancer, is the PTEN gene.
The PTEN gene aberration is associated with several diseases such as Cowden
disease, Autism, Lhermitte Duclos, Bannayan-Zonana syndrome and cancer.71 In 1997,
Li eta! and Steck eta! first identified a high frequency of PTEN mutations and deletions
in cancers of the brain, bladder, breast, and prostate, implicating PTEN as a novel tumor
suppressor in tumorigenesis.20’72 Likewise, Yu et a! demonstrated that inactivation of
PTEN was the result of point mutations, epigenetic silencing, and deletions.
PTEN is a member of the type-I protein tyrosine phosphatase (PTP) family and
consists of five domains, namely (i) N-terminus phosphoinositol 4, 5 bisphosphate (PIP2)
binding domain, (i) the phosphatase domain, (iii) lipid binding C2 domain, (iv) PDZ
(post synaptic density protein 95 (PSD95)), Drosophila disc large tumor suppressor (DIg
A), and zonula occludens-1 protein (zo-1)) motif and (v) a C-terminal tail containing a
PEST motif.24 The N-terminus phosphatase domain has dual-specificity activity that
dephosphorylates protein and phosphoinositide substrates.73 The peptide phosphatase
activity is targeted against tyrosine, serine, and threonine residues indicating that PTEN
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targets a wide range of molecules and subsequent cellular functions. The lipid
phosphatase activity of PTEN dephosphorylates phosphatidylinositol 3, 4, 5-phosphatase
(PIP3), a product of P13K, to form PIP2 and as a result, negatively regulates AKT
activation.
It is well established that PTEN is involved in regulating a variety of cellular
functions, such as (i) apoptosis; (ii) cell cycle; (iii) cell adhesion; and (iv) cell migration.
Studies have shown that PTEN expression in cancer cells sensitized cell to death
receptor-mediated apoptosis, which was induced by TNF, TRAIL as well as the
activation of the FADD-dependent pathway.74 In other studies, PTEN modulated cell
growth by inhibiting cdc6 and cyclin E2 levels, which resulted in G1 cell cycle arrest.75
Furthermore, PTEN targeted the tyrosine residue on focal adhesion kinase (FAK), which
disrupted cell adhesion and migration.76
The regulation of PTEN function follows a complex mechanism at both the
transcriptional and post-transcription levels. Interestingly, the tumor suppressor p53 has
been shown to up regulate the PTEN transcription.77 Additionally, PTEN can inhibit
MDM2 nuclear entry, thus promoting p53 nuclear functions.78 Currently, there are
several post-transcriptional modifications that regulate PTEN functions. These are: (i)
phosphorylation, (ii) nitrosylation, (iii) ubiquitination and (iv) oxidation.7982 Notably,
reactive oxygen species (ROS) accumulation reversibly inactivates PTEN by causing the
formation of a disulphide bond between Cys124 and Cys7l in the active site of PTEN.7
ROS-mediated inactivation of PTEN resulted in the activation of P13K, and subsequent
accumulation of PIP3.8 This report suggested that the loss of PTEN provides a
permissive switch for P13K signaling pathway.
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In prostate cancer, studies have shown that 60% of advanced prostate cancer
exhibits a loss of PTEN, indicating that the loss of PTEN promotes prostate cancer
development and progression.2°Additional studies have shown that complete loss of
PTEN is an early prognosis factor in prostate cancer metastasis.84 Furthermore,
compelling evidence shows that loss of PTEN promotes androgen-independence in
prostate mouse model. Abate-Shen eta! showed that loss of PTEN resulted in the
activation of AKT and ERK, whereby AKT directly activates androgen receptor (AR) to
promote androgen-independence.85
2.7 Reactive Oxygen Species (ROS) Signaling
Reactive oxygen species are oxygen-derived free radicals, such as superoxide
anion (O{), hydroxyl radicals (0H), peroxyl (R02), and oxygen-derived nonradical
species like hydrogen peroxide (H20).86 The major cellular source of ROS is through
the mitochondrial complexes I and III, where electrons from NADH or FADH2 react with
oxygen to produce superoxide anions.86 ROS is also produced in the cytosol by
intracellular enzymes such as oxidases, lipoxygenases and cyclooxygenases (Figure 3)86
It is well established that ROS is implicated in oxidizing biomolecules such as DNA,
lipids and protein, which over time can lead to cell death.8789 Under physiologic
conditions, to prevent cellular damage, cells have developed several antioxidant systems
to defend against the deleterious effects of ROS. Some of the main antioxidant systems
used to maintain ROS homeostasis are the glutathione, thioredoxin, superoxide dismutase
(SOD) and catalase systems.9°
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Interestingly, accumulating studies show that ROS plays a critical role in
regulating normal cellular function through gene transcription, cell signaling and post-
translational modification.91’2 It has been recognized that loss of ROS homeostasis








Figure 3: Schematic showing the main sources of ROS and downstream targets in cancer cells.
2.8 The Role of ROS in Cancer
Tumorigenesis is characterized by a profound reprogramming of the genome,
which ultimately activates oncogenes and inhibits tumor suppressor genes. Part of this
reprogramming is due to elevated levels of ROS, which occurs as a result of the close





pyrimidine and deoxyribose residues.96 In cancer cells, increased ROS accumulation is
generally due to loss of antioxidant or increased expression of pro-oxidants. For instance,
Nelson eta!. have observed somatic silencing of glutathione S-transferase (GSTP1), a
member of cellular antioxidant system, in almost all prostate cancer cases that were
investigated.97 In addition to prostate cancer, GSTPI is also silenced in various other
malignancies such as hepatocellular carcinoma and breast cancer cells.98’9 Conversely,
cancer cells induce ROS generation through the expression of various pro-oxidants
molecules such as NOX, PUMA and changes in mitochondrial functions. Additionally,
current evidence suggests that the tumor microenvironment, consisting of immune cells,
fibroblast cells and stromal cells, work together to enhance the production of ROS,
thereby promoting cancer progression.’°° Together, the source of ROS in cancer cells
depends mainly on the loss of antioxidant mechanisms and gain of pro-oxidant
mechanisms to facilitate tumor development and progression.101
It is well established that ROS functions as a secondary-messenger that regulates
cell survival pathways and ultimately promotes malignant transformation and
progression. 102 Emerging evidence indicates that ROS also functions by promoting post
translation modification of kinases, phosphatases, tumor suppressors and oncogenic
molecules, such as kinase p2lras, PTEN, p53 and HIFhx, respectively.7’103 Studies have
shown that ROS mediates cell survival and metastasis by regulating various signaling
pathways such as the PI3K!AKT and MAPK/ERKI/2 pathways in several cancer models,
such as prostate, breast and leukemia.6’104 Hydrogen peroxide activated the MAPK
pathway to provide cellular protection and proliferation in response to oxidative stress,
which correlated with sustained activation of Protein Kinase C (PKC).10’106 Ha eta!.
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described how ROS activated hepatocellular carcinogenesis via dysregulation of PTEN
and AKT.107 Several studies have also observed an inactivation of PTEN catalytic
activity by ROS, which correlated with increased expression of phosphorylated AKT (p
AKT).92’107 ROS also regulates transcription factors, directly or indirectly, resulting in
cell cycle induction and apoptosis suppression.108 Transcription factors such as Spi,
glucocorticoid receptor and Egri were described as redox-sensitive, and underwent
modification of their DNA-binding domains or posttranslational modification sites to
promote or inhibit gene expression)°9”1
2.9 The Role of ROS in Prostate Cancer
There is considerable evidence suggesting that ROS production contributes to the
pathogenesis of prostate cancers.112 In fact, Kumar et al. have demonstrated that
advanced metastatic prostate cancer cells produce higher amounts of ROS compared to
less metastatic cancers; suggesting that the gradual accumulation of ROS is associated
with the progression of prostate cancer.6 Recent studies suggest that this increase in
oxidative stress in prostate cancer is due to the dysregulation of antioxidant/pro-oxidant
balance. Currently, there is little known about the underlining cause for this imbalance.
However, strong evidence indicates that androgen plays a crucial role in inducing ROS
generation by increasing the pro-oxidant molecule NOX.’13 Conversely, the loss of
antioxidant molecules have also been observed in prostate cancer cells. The transcription
factor, erythroid 2p45 (NF-E2)-related factor 2 (Nef 2), promote the expression of key
antioxidative enzymes by binding to the antioxidant response element (ARE). In prostate
cancer, the expression of Nef 2 and several of its target genes are significantly
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downregulated. Therefore, the delicate balance between the antioxidant and pro-oxidant,
dictate whether ROS-mediates cells survival or cell death. Hence, at the ideal level of
ROS , cells undergo malignant transformation.
The mitochondria is a major source of ROS; hence, changes to its function
typically results in ROS accumulation. Therefore, changes to mitochondrial function and
mutation of mitochondrial DNA (mtDNA) is associated with the malignant
transformation of prostate cancer.114 The rate of glucose metabolism and the acidic
environment of prostate tumors are factors that influence mitochondrion functions, which
enhance ROS production and, ultimately promote prostate cancer metastasis.115’116
In advanced prostate cancer, ROS also facilitates various cellular functions such
as survival, proliferation and migration through the activation of signaling pathways,
such as the MAPK and PI3K/AKT pathways.’17’118 In addition to signaling molecules,
studies have shown that ROS also activates various transcription factors including HIFIu,
Ap-1 and NF-KB, that significantly contribute to malignant transformation prostate
cancer)’9’120 The activation of these transcription factors typically induces the
expression of several oncogenic molecules. For instance, the activation of HIF1c is has
been shown to promote metastasis and angiogenesis through VEGF secretion. Despite
the vast amount of study done, the mechanism by which 1-hF I c is activated and the
downstream genetic response is poorly understood. Additionally, recent studies have
shown that ROS inactivates PTEN and subsequently activates P13K pathway in immune
and human kidney cells, implicating ROS as a possible oncogenic signal that can promote
malignant transformation by inactivating PTEN.83’121
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2.10 Hypoxia Inducible Factor (HIF) la
The state of reduced oxygen levels below normal levels is defined as hypoxia.
Hypoxic conditions occur under various physiologic conditions such as embryonic
development, adaptation to high altitude, and wound healing.122 Hypoxic (low
concentration of oxygen) conditions are also present in various diseases including
ischemic diseases and cancer.122 During hypoxia, cells react by up regulating hypoxia
inducible factor (H IF), which enhances the expression of a unique group of targeted
genes involved in adjusting to low oxygen concentration. The HIFI transcription factor
is a heterodimer that consists of a regulatory HIFHi subunit and the constitutively
expressed HIF 113 subunit. Both subunits are members of the basic helix-loop-helix
(bHLH) and PER-ARNT-SIM (PAS) superfamily of transcription factors.123 The domain
structure of HIFIa includes an oxygen-dependent degradation domain (ODD), an N-
terminal activation domain (NAD), and a C-terminal activation domain (CAD).124
Conversely, HIF 113 contains only the bHLH, CAD, and PAS domains.
HIFIa activation relies on an oxygen-dependent or an oxygen—independent
mechanism. Under normoxic (normal physiologic concentration of oxygen) conditions,
oxygen promotes the rapid degradation of HIF-ct via the 26S proteosome.’25 Under
normoxic conditions, proly hydroxylase domain proteins (PHDs) hydroxylate two
prolines residues on the ODD domain of HIF. The Hydroxylated HIF1 interacts with the
von Hippel-Lindau (VHL) protein, which promotes the ubiquitination of HIF-a for
proteasomal degradation.’26 However, under hypoxic conditions, PHDs are inactivated
which results in the inhibition of HiFici ubiquitination and ultimately, degradation. The
accumulation ofHlFlct translocates to the nucleus, dimerizes with HIF-f3 and promotes
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gene transcription by binding to hypoxia-responsive element (HRE). The oxygen-
independent mechanism for the regulation ofHIFlct is mediated by various signaling
pathways such as the ROS, ERK1/2 and PI3K/AKT pathways.127’128 The activation of
PI3K/AKT has been shown to activate the CREB-binding protein (CBP)/p300, which is
involved in stabilizing interaction of HIF heterodimmer with HRE to promote gene
transcription.129 Recent studies have suggested that activated ERKI/2 promotes HIFlc
transcriptional activity.130’131 Collectively, these studies suggest that both PI3K/AKT and
ERKI/2 are positive regulators ofHIFl transcriptional activity. However, it is unclear
whether this signaling axis exists in prostate cancer. A survey of malignant tissues
showed an increase in expression ofHlFlcL and HIF2u in bladder, breast, colon and
prostate tumors.132 In prostate cancer, 1-IIF expression has been determined to increase
relative to its respective normal epithelium, stromal cells, and benign prostatic
hyperplasia.133 This suggests that up-regulation of HIF is an early event in prostate
tumorigenesis, which also mediates various metastatic events such as angiogenesis,
metabolism, proliferation and metastasis. In spite of large volumes of studies conducted,
the underlining mechanism for the up-regulation of HIF in prostate cancer remains
unclear.
2.11 The role of ROS on CXCR4
In cancer and other cell models, CXCR4 and SDFlc are up-regulated in high
ROS concentrations and/or hypoxic environments where oxygen levels are reduced
below normal.134’22 In these conditions, cells react by inducing expression of a HIFI
transcription complex, which enhances the expression of a unique group of targeted
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genes involved in adjusting to low oxygen concentrations. The H1F1a subunit acts as a
transcription factor for CXCR4 by binding to the H1FIu response element (HRE) found
on the promoter region of CXCR4.135 Therefore, a tumor microenvironment that is rich
in ROS may critically influence CXCR4-mediated expression and functions, which will
ultimately promote cancer progression. A survey of malignant tissues demonstrated an
increase in HiFict expression in bladder, breast, colon and prostate tumors, which
correlated with CXCR4 and SDF1ct expression in breast tumors.132’133. 136
The notion that ROS regulates CXCR4 expression and function is fairly new in
cancer research. Wu et al. described that ROS sustained PKC and ERK1/2, which led to
EMT-like scattering, migration, and reduced growth of hepatoma cells.’°6 Models of
ROS regulation of CXCR4 is scarcely described, but has been demonstrated in the
immune cells. Lee ci’ al. demonstrated that depletion of ROS by N-acetylcysteine (NAC)
promoted CXCR4-mediated activation of the AKT pathway in B-cells.’37’138 Lin ci’ al.
described that CXCR4 induced ROS production in hematopeoic stem cells.’39
Additionally, loss of ROS reduced secretion of SDFIcL from human bone marrow
osteoblasts cells and endothelial cells.’4°
High amounts of ROS is used in current therapy to induce apoptosis in tumors.
Drug, such as anthracyclines and epipodophyllotoxins are used to induce ROS
accumulation in cancer cells, hoping to create oxidative stress and cell death.’41 Our
findings in prostate cancer cells, along with immune studies, demonstrate that ROS may
act as an inducing molecule resulting in cell survival mechanisms. Specifically, ROS
may increase CXCR4 expression in cells to escape oxidative stress and avoid death. The
accumulation of ROS has been shown to activate survival pathways in cancer cells.’42’143
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In our studies, we observed an increase in p-AKT expression. Phospo-AKT activates
HIF 1ff, which may have led to the correlating increase in CXCR4. H1FIa recognizes the
HRE promoter region on CXCR4, resulting in increased transcription.136
Concentrations of ROS have been generally considered apoptotic in cancer cells.
We believe that the concentration should be reconsidered since survival mechanisms and
metastasis can be induced. Several key questions remain about ROS and CXCR4-
mediated cancer progression, such as (1) whether survival mechanisms have already been
activated in the primary tumor; or (2) whether primary tumors induce survival
mechanism after exposure to ROS, hypoxia and other deleterious microenvironments.
CHAPTER 3
EXPERIMENTAL PROCEDURES
3.1 Cell Culture, Antibodies and Reagents Conditions
LNCaP, DU145, 22Rv1 and PC3 human prostate cancer cell lines and 293T
human embryonic kidney cell line were obtained from American Type Culture Collection
(Manassas, VA). The C42 human prostate cancer cell lines were a kind gift from Dr.
Leland Chung. PC3, LNCaP, C42, DU145 and 22Rv1 cells were maintained in RPMI
1640 containing 10% fetal bovine serum (FBS), 1% non-essential amino acids and 1%
antibiotic-antimycotic at 37°C in 5% CO2. Human bone marrow endothelial (HBME)
cells were a kind gift from Dr. Russell Taichman (University of Michigan School of
Dentistry), and maintained in complete DMEM media (10% FBS, 1% nonessential amino
acids and 1% antibiotic-antimycotic).144 All cells were maintained at 60% to 80%
confluency. PD98059 was purchased from Sigma Aldrich; LY294002 was purchased
from Cayman Chemicals; RPM! and DMEM media were obtained from MediaTech;
SDF1cL was obtained from PeproTech. Human antibodies used were anti-PTEN, anti
AKT, anti-phospho-AKT and anti-phospho-ERKI/2, which were obtained from Cell
Signaling (Danvers, MA). Anti-ERKI/2 was obtained from Biosource (Camarillo, CA);
anti-GFP and Fusin-CXCR4 were obtained from Santa Cruz Biotech (Santa Cruz, CA).
Anti-HIF 1 c was obtained from BD Biosource (Sparks, MD). Hydrogen peroxide (H20)
was used as our model of ROS which was obtained from Acros Organics (Belgium).
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AMD3 100 and N-acetyl-cysteine (NAC) were from Sigma Aldrich; N-ethylmaleim ide
and Cobalt Chloride were from EMD Chemicals.
3.2 Plasmid Construct
PTEN (pcDNA3-GFP-PTEN) and GFP (pcDNA3-GFP) constructs were
generated as described previously.145 Briefly, the GFP sequence was cloned into the 5’
end of pcDNA3 plasmid (Invitrogen, Carlsbad, CA) using the HindilI and BamHI
restriction enzyme sites to generate pcDNA3-GFP. The coding sequence for human
PTEN was cloned into the Bami-JI and EcoRI sites of pcDNA3-GFP plasmid to generate
the pcDNA3-GFP-PTEN construct.
3.3 Western Blot Analysis
Cells were grown on 10 mm dishes, washed with PBS and harvested in lysis
buffer containing 20 mM Tris-HCI (pH 7.5), 150 mM NaCI, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM
Na3VO4,1 jig/mI leupeptin and 1mM PMSF (Cell Signaling). Protein concentrations
were estimated using Bradford protein assay (BioRad, Hercules, CA). Equal
concentrations of total cell protein were resolved by 10 % SDS-PAGE and transferred to
a polyvinylidene fluoride transfer membrane (PVDF). Non-specific binding sites were
then blocked with 5% nonfat dry milkJO.1% Tween 20/IX TBS (TBST) followed by an
incubation with primary antibodies for the protein of interest in 3% BSA-TBST (p-ERK,
p-AKT, AKT, PTEN, GFP) or 3% nonfat dry milk-TBST (ERKI/2, HIFIUL, CXCR4,
Tubulin). Membranes were washed in IX TBST, and incubated in horseradish
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peroxidase-conjugated anti-rabbit (p-ERK, p-AKT, AKT, PTEN, CXCR4) or anti-mouse
secondary antibodies (ERK 1/2, H1FIu, Tubulin) (Jackson immunoResearch) (1:2,000)
in 3% BSA-TBST or 3% nonfat dry milk-TBST for 1 hour at room temperature.
Immunoblots were visualized using Super Signal West Pico chemiluminescence reagent
(Thermo Scientific).
3.4 PCR Amplification
Total RNA was isolated with Total RNA Kit-I (Omega Bio-TeK,Norcross, GA),
as described by the manufacturer. Total RNA was reversed transcribed with M-MLV
transcriptase (Promega, Madison, WI) to generate cDNA for PCR amplification. Specific
sense and antisense primers for PTEN and housekeeping gene L19, were synthesized by
Integrated DNA Technologies as follows: PTEN (forward GGA CGA ACT GGT GTA
ATGATA TG; reverse TCTACTGTTTTTGTGAAG TACAGC), MMPI3 (forward TAT
CCG AGA CTA ATA GAA GAA GAC; reverse GGA ATT TGC TGG CAT GAC G),
MMPI4 (forward GAA GCA GGC CGA CAT CAR G; reverse CAG GAA GATGTCATT
TCCATTCAG) and L19 (forward GAA ATC GCCAATGCC TC; reverse TCTTAA CCT
CGA GCC TCA).
3.5 Flow Cytometry Analysis
Cells (lx 106) were plated in 100-mm dishes, and serum starved overnight for
synchronization of cell cycle. Cells were detached with IX citric saline and fixed in 4%
paraformaldehyde at 4°C for 30 minutes. Cells were washed in IX PBS, followed by
centrifugation at 3000 rpm. Non-specific binding sites were blocked in blocking buffer
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(1% donkey serum in IX PBS) at 4°C for 1 hour, followed by an incubation overnight in
CXCR4 antibody (1:100 dilution) (Fusin-CXCR4 mouse antibody) in blocking buffer at
4°C or without CXCR4 antibody (control). Cells were washed once in IX PBS, followed
by an incubation in fluorescein isothiocyanate (FITC) or Indocarbocyanine (Cy3)
fluorophore-conjugated secondary antibodies (1:500) (Jackson lmmunoResearch, West
Grove, PA) in blocking buffer at 4°C for 45 minutes. Cells were washed, resuspended in
IX PBS and the surface expression of CXCR4 was analyzed by flow cytometry (Accuri
C6, Ann Arbor, MI). Results were quantified using GraphPad Prism 5 statistical
program.
3.6 Transient Transfection
Transient transfections of pcDNA3-GFP or pcDNA3-GFP-PTEN were performed
in PC3 cells using Lipofectamine2000 (lnvitrogen, CA). Briefly, cells (5x10D) were
plated in a 6-well dish and transfected at 37 °C in 5% CO2 for 8 hours prior to the
addition of RPMI/10% FBS overnight. The next day, cells were serum starved or
harvested. Transfection efficiency was monitored by visualization of GFP using a Zeiss
Axiovert 200M fluorescence microscope.
3.7 Migration Assay
Cell migration assays were done using 8 jim pore transwell chambers (Costar,
Corning, NY). Briefly, cells were grown in starvation media for 24 hours prior to
detachment with 1 x citric saline. Cells were resuspended in RPMI media, and 2x104
cells/well were added to the upper transwell chamber. RPMI containing 100 ng/mL of
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SDF1cL was added to the lower chamber, and the transwell inserts containing cells were
placed in contact with the lower chamber. Cells were allowed to migrate towards SDF 1 u
in the lower chamber for 4-6 hours at 3 7°C. Cells that remained in the upper chamber
were removed with a cotton swab, and fixed and stained with Hemacolor Solution 3 Kit
(EMD, Gibbstown, NJ). Migrated cells were counted using a Zeiss Axiovert 200M light
microscope. Results were quantified using GraphPad Prism 5 statistical program.
3.8 Invasion assay
Transwell chambers (8-mm pore) (Costar) were coated with 40 iiL of Matrigel
(BD Scientific) gel mixture, and allowed to solidify for 1 hour at 37°C. Briefly, cells
were grown in starvation media for 24 hours prior to detachment with I x citric saline.
Cells were resuspended in RPMI media, and Ix cells per well were added to the upper
Transwell chamber. RPMI containing the various treatments was added to the lower
chamber and cells were allowed to migrate toward the lower chamber for 24 hours at
37°C. Cells that remained in the upper chamber were removed with a cotton swab, fixed,
and stained with Hemacolor Solution 3 Kit (EMD). Invaded cells were counted using a
Zeiss Axiovert 200M light microscope. Results were quantified using GraphPad Prism 5
statistical program.
3.9 Transendothelial Assay
Transwell insert chambers with 8im pores (Costar) were coated with 30 tL of
Matrigel (BD Scientific) gel mixture (1:1 in RPMI) and allowed to solidify for2 hours at
37°C. HBME cells (4xl0 cells/transwell) were seeded on top of matrigel and allowed to
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form a monolayer. DU145 cells were harvested in starvation media for 24 hours prior to
detachment with I x citric saline. lx cells were resuspended in RPMI media, and
added to the upper transwell chamber insert. RPM[ containing various treatments of
1-1202, AMD3J 00 and NAC were added to the lower chamber, and cells in the upper
chamber were allowed to invade the HBME monolayer and matrigel and migrate towards
the various treatments in the lower chamber for 24 hours at 37°C. Matrigel and cells that
remained in the inner upper chamber were removed with a cotton swab, and the outer
upper chamber was fixed and stained with Hemacolor Solution 3 Kit (EMD). Invaded
cells were counted using a Zeiss Axiovert 200M light microscope. Results were
quantified using GraphPad Prism 5 statistical program.
3.10 Proliferation Assay
Cell proliferation was assessed by MTT (Trevigen, Gaithersburg, MD) dye
conversion at 570 nm following the manufacturer’s instructions. In triplicates, I x l0
cells per well were seeded in a 96-well flat-bottomed plate. Cells were serum-starved for
24 hours, then treated with 100 ng/mL of SDF 1 a at 37 °C in 5% CO2. After each time
point (24 and 48 hours), 10 .tL of MTT reagent was added to each well and incubated for
2 hours at 37°C. Cells were then incubated in 100 iL of detergent reagent at 37°C for 2
hours. Proliferation was measured using a micro-plate reader (Bio-Tek Synergy HT,
Winooski, VT). Results were analyzed using GraphPad Prism 5 statistical program.
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3.11[H]Thymidine Incorporation
Cells were plated at a density of 4x cells/well in 24-well culture plates and
transfected with pcDNA3-GFP or pcDNA3-GFP-PTEN plasmids as described
previously. Cells were serum starved for 24 hours prior to incubating with lOOng/mL of
SDF1o at 37°C in 5% CO2. At each time point (24 and 48 hours), the media was
replaced with RPMI containing I .tCi/ml of [l-1] thymidine (PerkinElmer) and cells were
incubated for 4 h at 37°C. Cells were sonicated and filtered through Whatman DE8 I
filter paper discs using a vacuum pump prior to measuring the filter discs for radioactivity
incorporation using a LS6500 multi-purpose scintillation counter (Backman Coulter,
Brea, CA). Results were quantified using GraphPad Prism 5 statistical program.
3.12 Short Interfering RNA Transfection
Transient transfection of PTEN (siRNA; Cell Signaling) and H1FIa (5iRNA;
Santa Cruz) specific siRNA was performed on DU145 cells using Lipofectamine2000.
Briefly, cells (5x10) were plated in a 100-mm dish and transfected with 100 iM PTEN
siRNA or 10 nM HIF 1 cL-siRNA or scramble-siRNA (Santa Cruz) in serum-free media at
37 °C in 5% CO2 for 24 hours and 18 hours, respectively. Transfected cells were
harvested for western blot analysis of PTEN and H1F1L expression. DU145 cells knock
down with PTEN siRNA was serum-starved for a migration assay.
3. 13 Immunoprecipitation
Cells were washed once with ice-cold 1XPBS, followed by incubation in IX ice
cold cell lysis buffer for 5 minutes. Cells were then scraped and transferred into
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microcentrifuge tubes. Next, the cells were sonicated on ice three times for 5 seconds
each and then centrifuged for 10 minutes at 4°C, at maximum speed. The supernatant
was then be transferred into new tube and total protein concentration for each samples
were estimated by Bradford method. The primary antibody was added to 200 jiL
(lmg/mL) of cell lysate and incubated with gentle rocking overnight at 4°C. Protein-A/G
agarose beads (l5jiL) was then added and incubated with gentle rocking for 3 hours at
4°C. Next, the supernatant was centrifuged for 30 seconds at 4°C and the pellet was
washed, five times with 500iL of IX cell lysis buffer. The pellet was then resuspended
in 40iL of IX cell lysis buffer and analyzed with desired assay.
3.14 Western Blot Analysis of Alkylated PTEN
The oxidation state of PTEN was investigated using alkylating agents as
described by Lee et al . Briefly, after treatment cells (lx 106 cells) were scraped into 0.2
ml of Aklylating lysis buffer (20 mmol/L Tris-HCI (pH 7.5), 150 mmol/L NaCI, 1
mmol/LNa2EDTA, 1 mmol/L EGTA, 1% Triton, 2.5 mmol/L sodium pyrophosphate, I
mmol/L b-glycerophosphate, I mmol/L Na3VO4,I mg/mL leupeptin, lmmol/L PMSF,
2% SDS and 40 mM NEM) and then transferred to microcentrifuge tubes. The cell
suspensions were sonicated briefly and the protein concentrations were estimated using
Bradford protein assay (BioRad). The samples were then incubated at room temperature
for 30 minutes, then 60tg of total protein was resolved by 10% SDS-PAGE under non
reducing conditions. The separated proteins were transferred electrophoretically to a
PVDF membrane. Nonspecific binding sites were blocked with 5% nonfat dry milkJO.1%
Tween 20/1 xTBS, followed by incubation with anti-PTEN primary antibodies in 3%
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BSA-TBST. Protein complexes were detected with horseradish peroxidase-conjugated
secondary antibodies and enhanced chemiluminescence reagents (Pierce). The exposed
films were developed using an automated X-ray processor (Kodak X-OMAT M35A
Processor).
3.15 PTEN Phosphatase Assay
Treated cells (lx 106 cells/well) were harvested in IX lysis buffer (Cell Signaling).
500 jig of total protein were incubated with a PTEN specific primary antibody overnight
at 4°C, then immunoprecipitated with protein A/G agarose beads (Santa Cruz) for 4 hours
at 4°C. Samples were centrifuged for 10 minutes at 10,000 rpm, the supernatant was
collected and the bead pellet was then resuspended in 4OjiL of IX lysis buffer. Western
blot analysis was performed on total protein lysate, supernatant and bead pellets for
PTEN. The PIP phosphatase assay described by Maehama et al. was adapted to a 96-
well format.23 PIP3 lipid (Echelon, Salt Lake City, UT) was combined with 10j.iL of
immunoprecipitated PTEN and allowed to dephosphorylate PIP3 to PIP2 at 37°C for 2
hours. lOOjiL of malachite green was added to react with free phosphates, and the
absorbance for the phosphatase products was measured at 620 nm with a microplate
reader at increasing time intervals. Each data point was assayed in triplicate, and all
experiments were repeated at least three times.
3.16 Immunocytochemistry
Cells (3x104)were plated on glass slips in each well of a 10-mmplate. Cells were
washed with I xPBS, fixed with 4% paraformaldehyde, washed twice for 5 minutes
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inTris-glycine (0.1 mol/L glycine, pH 7.4), followed by a wash in IX PBS. Nonspecific
binding sites were blocked in blocking buffer (5% normal donkey serum, 1% BSA, 0.1%
Tween 20 in PBS) for 30 minutes, followed by incubation overnight with CXCR4
antibody (1: 100) in blocking buffer at 4°C. Cells were washed thrice in lx PBS, followed
by an incubation in Cy3-conjugated secondary antibody (1:500) in blocking buffer for 45
minutes in the dark at room temperature. Cells were washed thrice in I xPBS, followed
by incubation in 40,6- diamidino-2-phenylindole (DAPI; Sigma; 1:500 in PBS) for I
minute. Glass cover slips were washed in 1 x PBS before mounting on microscope slides
with AquaPolyrnount (Poly-Sciences, mc). Fluorescence was analyzed by Lising a Zeiss
Axio Imagwe.zl fluorescence microscope. Sterile glass covers lips were placed in each
wells of a 6 well plate followed by plating of DU145 cells. The cells were then be serum
starved overnight and treated with the indicated concentrations of H20 for 1 hour at
37°C in a 5% CO2 incubator. Next, cells were washed twice in IXPBS and then fixed in
4% paraforrnaldehyde/PBS for 20 minutes at room temperature. After fixing, the cells
were washed thrice with 1xPBS, then incubated in 0.1% Triton X-100/PBS for 15
minutes at room temperature. Cell were then incubated in blocking buffer (10% goat
serum/PBS) for I hour at room temperature. Next, the cells were incubated in primary
antibody at 4°C, overnight. Cells were then washed thrice in 1 xPBS for 10 minutes,
followed by incubation in secondary antibody for 2 hours at room temperature in the
dark. Next, cells were washed thrice in 1 xPBS for 10 minutes in the dark and then
incubated in diluted DAPI for 10 minutes in the dark. Cover slips were then mounted
onto glass slides using mounting media. Slides will then be visualized using a Zeiss
Axiovert 200M fluorescence microscope using the appropriate filters.
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3.17 Apoptosis Assay
Annexin-V FTIC Apoptosis Detection Kit Plus (MBL, Woburn, MA) was used to
quantify the levels of apoptosis in samples, according to the manufacturer’s
specifications. Briefly, cells were trypsinized, centrifuged and resuspended in 500iil of
IX binding buffer prior to adding Annexin V-FITC. After 15 minutes of incubation,
apoptosis was analyzed by flow cytometry (Accuri C6) for detection of Annexin V-FITC.
3.18 Statistics and Quantifications
Data are presented as the mean ± SE of at least three independent experiments.
The data was analyzed for two-way ANOVA or Student t-test. All statistical analyses
were done, and all graphs generated, using GraphPad Prism 5.0 software (GraphPad).
CHAPTER 4
RESULTS
4.1. Loss of PTEN permits CXCR4-mediated function through ERK1/2 in prostate
cancer cells
4.1.1 PTEN Is Differentially Expressed in Prostate Cancer Cells While CXCR4 is
Expressed.
On the basis of the reports that PTEN haplosufficiency is strongly correlated with
the conversion of prostate tumors to an invasive adenocarcinoma, and the observations
that CXCR4 is highly expressed in advanced prostate tissues, it was suggested that the
absence of PTEN permits CXCR4-mediated functions and development of an aggressive
phenotype in prostate cancer.22’8146,147 We first analyzed for the expression of PTEN at
the protein level among prostate cancer cell lines (PC3, LNCaP, C42, and DU145) by
western blot analysis, where 40 micrograms of total protein were analyzed for using a
PTEN specific antibody and total ERKI/2 served as a loading control (Figure 4 A). In
this experiment, we observed that PTEN was expressed in DU145 cells and positive
control human embryonic kidney cells, 293T (Figure 4 A), but was absent in LNCaP,
C42 and PC3 cell lines (Figure 4 A). To confirm these observations, analyzed for PTEN
expression at the mRNA levels. To accomplished this, 2 micrograms of total RNA were
isolated and reverse transcribed to cDNA for PCR amplification using primers specific
for PTEN and L19, which served as a loading control (Figure 4 B). As expected we
observed expression of PTEN mRNA in DU145 and positive control 293T cells, but not
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in PC3 (Figure 4 B). Interestingly, we also observed PTEN mRNA expression in LNCaP
and C42 (Figure 4 B). Genetic studies have shown that DU145 cells carry one functional
PTEN allele whereas the other allele is deleted, explaining why we detected expression of
PTEN 148 LNCaP cells carry a base pair deletion found on codon 6 of PTEN, resulting in
loss of translation.148 C42 cells are a metastatic derivative of LNCaP isolated from the
bone, which carries the same PTEN mutational pattern)49 Furthermore, PTEN was not
detected in androgen-independent PC3 cells at both the protein and mRNA levels, due to
homologous deletions of the PTEN gene (Figure 4 A and B).148 The PTEN expression
profiles observed in PC3, LNCaP, and DU145 cells are concurrent with previously
published data.’5°
It has been observed that CXCR4 is expressed in various cancer models,
including prostate.15’ The cell surface expression of CXCR4 in PC3, LNCaP, and
DU145 cells were analyzed by flow cytometric analysis. PC3, LNCaP, and DU145 cells
were chosen for this assessment because PC3 and LNCaP are absent for PTEN protein
and DU145 cells express functional PTEN. Because PC3 cells are representative of an
androgen-independent model, C42 cells were excluded. PC3, LNCaP and Du145 cells
were fixed in 4% paraformaldehyde, blocked in 1% donkey serum/PBS, and probed with
a CXCR4-specific antibody. CXCR4 was detected with a FITC-conjugated donkey anti
mouse antibody. Cells were analyzed for FITC fluorescence intensity by flow cytometry.
From these experiments, we found that CXCR4 was expressed on the cell surface of all 3
cell lines, as detected by the positive shift in fluorescence (redline) compared with
background control (black line, Figure 5 A). Quantitatively, these data revealed a 5-fold
increase in overall fluorescence intensity of CXCR4 over background (control) in PC3
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cells whereas LNCaP and DU145 cells revealed an increase of 20- and 15-folds,
respectively (Figure 5 B). These values were standardized against the values of the
background (control), which contained secondary antibody only.
Taken together, these results indicate that loss of PTEN is commonly observed in
advanced prostate cancer cells. CXCR4 is not expressed in normal prostate cells, but is
expressed in prostate cancer, where it enhances cell metastasis.146 Hence, the expression
of CXCR4 in prostate cells may be indicative of prostate cancer development, and may










Figure 4: PTEN is differentially expressed in prostate cancer cells (A) Analysis of
PTEN expression by western blot analysis in prostate cancer cell lines. (B) Analysis of
























































































































4.1.2 Reconstitution Of PTEN Does Not Modulate the Expression and Subcellular
Localization of CXCR4
Although a functional relationship has not been elucidated, Carver et al. observed
a correlation in expression between PTEN and CXCR4 in prostate cancer.28 To address
this relationship, PTEN expression was reconstituted in PC3 cells, as they are androgen
independent and highly metastatic and represent an advanced stage of prostate cancer.
PC3 clones were generated by transiently transfected with PTEN (pcDNA3-GFP-PTEN)
Figure 6: The expression of PTEN does not modulate the expression of CXCR4
in PC3 cells.
or GFP (pcDNA3-GFP) prior to fixing with 4% paraformaldehyde and blocking in 1%
donkey serum/PBS andthen probing with a CXCR4-specific antibody. Our clone
expressing PTEN was then analyzed for CXCR4 expression to determined whether
PTEN modulate CXCR4 expression. We observed that PTEN did not affect the surface
expression of CXCR4 in PC3 cells (Figure 6), nor did PTEN expression affect the diffuse
subcellular localization of CXCR4, compared with control (Figure 7). From these we






Figure 7: The expression of PTEN (green) does not modulate the subcellular localization





4.1.3 PTEN Induced a Mesenchymal-To-Epithelial Morphological Change.
Interestingly, by microscopy we observed a morphologic change in PC3-PTEN
cells compared with PC3-GFP cells, 48 hours post-transfection with pcDNA3-GFP and
pcDNA3-GFP-PTEN constructs. Light micrograph (Figure 8) and fluorescence
micrographs (Figure 9A) were taken 48h post-transfection at lox magnification using a
Zeiss Axiovert 200M fluorescence microscope. We observed that both PC3 and PC3-
GFP cells showed a mesenchymal like morphology, as represented by lamellipodia- like
projections (Figure 8). However, PC3-PTEN cells showed an epithelial like morphology
compared with PC3 and PC3-GFP cells (Figure 9 A). In agreement with our
observations, Kotelevets et al. observed that canine kidney epithelial cells transfected





Figure 8: Micrographs show a morphological change from a mesenchymal
phenotype in (A) PC3 and (B) PC3-GFP to an epithelial-like in phenotype as
seen in (B) PC3-PTEN.
like cells transfected with PTEN mutants.’52 To further investigate this morphologic
transition, we analyzed the expression pattern of vimentin, an EMT marker (Figure 9 B).
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Figure 9: Transient transfection of PTEN into PC3 cells induced EMT marker
vimentin. (A) Transfected PC3 cells showing PTEN-GFP expression. (B)
Transfected cells analyzed for vimentin expression which showed a decrease in
expression. The graph represents the relative expression of vimentin compared to
control. (C) Transfected PC3 cells showing the expression of PTEN that was
expressed from the plasmid. (*, p <0.05).
GFP cells. Copy DNA constructs were labeled with GFP; therefore, we utilized
fluorescence microscopy to confirm that PTEN was expressed in these epithelial like
cells. We detected GFP-PTEN fusion protein at the cell membrane of PC3-PTEN cells,
where it primarily functions (Figure 9 C). To ensure that cDNA constructs were







4.1.4 PTEN Expression Inhibited CXCR-Mediated Migration and Proliferation of
Prostate Cancer Cells.
Prostate cancer tends to spread to the bones. The CXCR4/SDFIa signaling axis
was shown to play a pivotal role in triggering prostate bone metastasis, whereas Wu et al.
observed that PTEN inhibited C42 cell migration toward calvaria-conditioned
medium.153’154 To examine whether PTEN negatively regulates CXCR4-mediated
migration and proliferation, cells were transiently transfected with 4 jig of pcDNA3-GFP
or pcDNA3-GFP-PTEN constructs, prior to serum starvation for 24 h. Cells (2x I Oj were
added to the upper transwell chamber and allowed to migrate towards 100 ng/mL of
SDFlo in the lower wells for 4 hat 3TC (Figure 10 A & B). Micrographs of migrated
cells were taken at lox magnification using a Zeiss Axiovert 200M light microscope
(Figure 10 A). Five fields of each transwell insert were randomly selected and counted
for migrated cells at lOX magnification and graphically represented (Figure 10 B). From
this experiment, we observed an increase in cell migration of PC3 and PC3-GFP cells
toward SDFIa in the bottom chamber (Figure 10 A). However, SDFIct failed to
stimulate movement of PC3-PTEN cells (Figure 10 A), resulting in a significant
reduction in cell migration compared with PC3 and PC3-GFP cells (Figure 10 B). To
further investigate the regulatory role of PTEN in CXCR4-mediated functions, PC3,
PC3-GFP, and PC3-PTEN cells were analyzed for proliferation and viability. By MTT
assay, we observed increases in the viability of both PC3 and PC3-GFP cells 48 hours
post treatment with SDF1cL (Figure 10 C). However, the viability of PC3-PTEN cells
was significantly reduced compared with PC3-GFP cells at both 24 and 48 hours post—
SDFIcL treatment (Figure 10 C). By [3H] thymidine incorporation assay, we observed
48
increases in proliferation in both PC3 and PC3-GFP cells 48 hours post—ligand treatment,
whereas the proliferation of PC3-PTEN cells was significantly reduced compared with
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Figure 10: PTEN expression inhibited CXCR4-mediated migration and
proliferation. (A) Micrographs showing transfected cells that migrated under SDFIu
treatment. (B) A graphical representation of total migrated cells. (C) Cell
proliferation assay of transfected cells under SDFIcL treatment. (D) Proliferation as
measured by [3Hj thymidine of transfected cells under SDFIa treatment. (*, P <
0.05).
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4.1.5 Suppression of ERK1/2 Phosphorylation Inhibited CXCR4-Mediated
Migration of PC3 Cells.
PTEN functions as a dual protein and lipid phosphatase. The major known
substrate of PTEN is the lipid second component, most notably the protein kinase
AKT.’ The subsequent activation ofCXCR4/SDF1u involves classical pathways of cell
survival: (i) PI3K/AKT, (ii) the MAPK cascade, and (iii) PLC-b.’56 Many reports have
observed AKT activation in response to SDFIu, whereas others have observed that
ERKI/2 activity is required for GPCR-mediated migration.’7’158 When we investigated
the basal levels of ERKI/2 and AKT in PC3-GFP and PC3- PTEN cells, we observed a
decrease in phospho-AKT expression in PC3-PTEN cells compared with PC3-GFP cells
(Figure 10 A). Phospho-ERKI/2 levels did not change (Figure 11 A). Treatment of
serum-starved PC3-GFP and PC3-PTEN cells with SDFIcx resulted in ERK1!2
phosphorylation in a biphasic manner, while no changes in AKT phosphorylation were
observed compared to control (Figure 11 B). Phospho-ERKI/2 was detected in PC3-GFP
cells upon SDF 1 c stimulation, but not in PC3-PTEN cells under the same conditions
(Figure 1 IB). To determine whether PTEN-mediated inhibition of ERKI/2
phosphorylation was responsible for the decreased CXCR4-mediated cell migration of
PC3-PTEN cells, we used 50mM of PD98059, a small molecule MEK inhibitor, to
suppress ERKI/2 phosphorylation, and 10mM of LY294002, a small molecule P13K
inhibitor, to suppress AKT phosphorylation. Pretreatment with PD98059 for 1 hour
abrogated SDF1cL induced phosphorylation of ERKI/2, whereas LY294002 abrogated
phospliorylation of AKT (Figure 12 A and B). Because we observed that PTEN blocked
SDF lu-induced phosphorylation of ERKI/2, we then determined whether ERKI/2
50
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Figure 11: PTEN inhibited CXCR4-mediated activation of AKT and ERKI/2. (A)
The expression of PTEN, p-AKT, total AKT, p-ERKI/2 and total ERKI/2
expression by western blot analysis (B) The expression of p-AKT, total AKT, p
ERKI/2 and total ERKI/2 in transfected cells showing the effect of PTEN on these
molecules.
cell migration assay of PC3 and PC3-GFP cells toward SDFIcL in the presence and
absence of LY294002 and PD98059. Five fields were randomly selected and counted for
migrated cells at lox magnification. Experiments were repeated thrice and data
represents the averages of three independent experiments. Pretreatment with PD98059
significantly inhibited PC3 and PC3-GFP migration, but was not inhibited by LY294002
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Figure 12: PTEN inhibited CXCR4-mediated migration by inhibiting ERKI/2
phosphorylation. (A) PC3 and (B) PC3-GFP cells were analyzed for the expression
of p-AKT, total AKT, p-ERK and total ERKI/2 specific antibodies. (C) PC3 and
(U) PC3-GFP cells migration potential were analyzed. (*, P < 0.05).
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4.1.6 Downregulation of PTEN Expression Enhanced CXCR4-Mediated Migration
of DU145 Cells.
PTEN inactivation correlates with invasiveness and metastasis in prostate cancers.
Loss of PTEN is common in prostate cancers that have transitioned to an advanced
disease. DU145 cells have low-to-moderate metastatic potential and express a functional
PTEN allele. Therefore, we tested whether downregulation of PTEN could serve as the
permissive switch for CXCR4-mediated migration. We utilized siRNA to down regulate
the expression of PTEN in DU145 cells. cells were transfected with PTEN specific
siRNA or scramble-siRNA using Lipofectamine2000. Fourty-eight hours post
transfection, cells were lysed and 30 jig of protein were analyzed for PTEN expression by
western blot analysis where 13-actin served as a loading control (Figure 13 A). Cells
transfected with a fluorescein-conjugated siRNA targeted for PTEN or control (scramble
5iRNA) were subjected to transwell migration assays toward SDF1cL (Figure 13 B). Cells
(2x104)were seeded into the upper chamber of transwell inserts and allowed to migrate
towards lOOng/mL of SDF1o for 6 hours at 37CC. Five fields were randomly selected
and counted for migrated cells at lox magnification. Experiments were repeated thrice
and data represents the averages of three independent experiments. Clones transfected
with PTEN siRNA exhibited decreased PTEN expression by Western blot analysis
(Figure 13 A) and a significant increase in migratory activity toward SDF lii (Figure 12
B), which was not observed in control transfected cells. These finding suggests that there
is a reciprocal relationship between CXCR4 activity and PTEN expression. Taken
together, these results support the idea that the loss of PTEN regulation permits the

















Figurc 13: PTEN downregulation enhanced CXCR4-mediated migration of DU145
cells. (A) Analysis of PTEN expression DU145 cells to confirm knocked down of
PTEN. (B) Migration potential of knocked down PTEN-DU 145 cells showing the




4.2. ROS Enhances CXCR4-mediated function through PTEN inactivation in
Prostate Cancer Cells
4.2.1 H20Inhibited PTEN Catalytic Domain in DU145 And 22Rv1 Cells.
The tumor suppressor PTEN negatively regulates the PI3K!AKT pathway by
converting PIP3 to PIP2; thus removing the signal that would have activated AKT.159 In
addition PTEN expression has also been implicated in negatively regulation other
signaling pathways such as the ERKI/2 signaling.17’160 Ha et al. found that exogenous
treatment of hepatocellular carcinoma with H20 resulted in a form of PTEN that was
oxidized within the catalytic domain.107 Consistent with these studies, we have
established that increased expression of p-AKT and p-ERKI/2 correlated with an
oxidized form of PTEN inH20-treated DU145 cells.92 Upon treating prostate cancer
cells with various concentrations ofH20 and 10 mM NAC, we first observed no
significant change in PTEN expression levels which was analyzed by western blot
analysis using a specific antibody where o-Tubulin served as a loading control (Figure
14 A). We determined whether H20 oxidizes PTEN by alkylation method and observed
a low molecular weight band, distinct from total PTEN, representing the oxidized form in
both cell lines (Figure 13 B).92 Consistent with H20,NAC did not affect PTEN
expression (Figure 14 A).
It has been reported thatH20-induced oxidation of PTEN results in a disulfide
bond between amino acids cysteine(s) 71 and 124 within the active site, thus inactivating
its phosphatase function.7 To determine whether oxidation disrupted the catalytic
function of PTEN, we treated cells with H20 and NAC, and analyzed activity by a
phosphatase assay in both cell lines. Following treatments, PTEN was
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Figure 14: H20 inhibited PTEN catalytic activity in DU145 and 22Rv] cells.
(A) Cells treated with H20 showed no change in PTEN expression. (B) Cells
were exposed to H20 followed by alkylation showing increase in oxidized
PTEN (inactive).
immunoprecipitated (Figure 1 5 A) and allowed to convert PIP3 (substrate) to PIP2,
which produces free phosphates, and ultimately, reacts with malachite green dye as the
functional output of phosphatase activity. DU145 and 22Rvl cells demonstrated a
moderate level of activity, which increased in the presence of ROS scavenger NAC, or
the absence of 0.25mM H20(Figures 15 B & C). Although the expression levels did
not change, H20 may have inactivated PTEN catalytically, which permitted increased
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Figure 15: H20 inhibited PTEN catalytic activity in DU145 and 22Rv1 cells. (A)
Western blot showing the expression of PTEN in cells treated with H20and NAC
then immunoprecipitated for PTEN. (B) Graph showing the PTEN protein
phosphatase activity assay under the indicated treatments.
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4.2.2 H20 Induced the Expression of Phosphorylated AKT and ERK1/2 in DU145
and 22Rvl
Previous studies have shown that exogenous H20 increases expression of
phosphorylated AKT (p-AKT) and phosphorylated ERKI/2 (p-ERK1/2) in DU145 cells
92 In support of our studies, Kumar et al. demonstrated that inhibition of endogenous
H20production decreased expression of p-AKT and p-ERKI/2 kinases.6 PTEN
expression has been shown to negatively regulate the PI3K/AKT and ERK1/2 pathway.
Hence, we investigated whether ROS-mediated inactivation of PTEN would promote the
upregulation of p-AKT and p-ERKI!2 in DU145 and 22Rv1 cells. We serum-starved
cells and treated with various concentrations ofH20 and 10 mM NAC. Forty
micrograms of total protein were analyzed for p-AKT and p-ERKI/2 expression by
western blot analysis using specific antibodies, where total AKT and ERKI/2,
respectively, served as loading controls. From our experiment, we found that H20
induced expression of p-AKT and p-ERKI/2 in DU145 cells; we observed a gradual
increase in expression of both kinases (Figure 16 A & B). We also determined whether
H20 induced expression of p-AKT and p-ERKI/2 in 22Rv1 cells, where we observed a
biphasic expression pattern of p-AKT, and gradual increase ofp-ERKI/2 (Figure ISA &
B) in a concentration-dependent manner. The increases in p-AKT and p-ERKI/2 were
blocked by 10 mM NAC, a ROS scavenger, indicating that expression was dependent on










Figure 16: H20 induced expression of phosphorylated AKT and ERKI/2 in
DU145 and 22Rv1 cells. (A) Analysis of p-AKT and (B) p-ERKI/2 expression
show a gradual increase following H20treatment.
4.2.3 H20Induced Expression of CXCR4 and HIF1a in DU145 but Not in 22Rv1
Cells.
The absence of PTEN expression has been reported to correlate with increased
expression of CXCR4 in DU145 cells and Jurkat T cells, and increased invasion and
migration of DU145 cells in a CXCR4-dependent manner.17’2692 To determine whether
inactivation of PTEN by H20 affected CXCR4 expression, DU145 and 22Rv1 cells were
treated with various concentrations of H20 and 10mM NAC and Forty ig of total
protein were analyzed for expression of CXCR4 by western blot analysis using specific
antibodies where a-Tubulin served as a loading control. We observed that cells treated
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with H20 and analyzed for CXCR4, showed an increased of CXCR4 in DU145 cells,
but did not change in 22Rv1 (Figure 17 A). NAC abrogated CXCR4 expression in
DU145 cells, but had no effect in 22Rv1 cells (Figure 17 A).
The observation that ROS increases CXCR4 expression has been shown in
mesenchymal stem cells 134, (3- lymphocytes 138 and prostate cancer.92 Since, we
observed that H20 induced expression of CXCR4 in DU145, but not in 22Rv1 cells, we
wanted to determine the mechanism by which CXCR4 is induced. Previous studies have
shown that, the expression of CXCR4 is transcriptionally regulated by H1F ict, a member
of the bHLH family of transcription factors.136 Direct application ofH20 to DU145
cells resulted in accumulation of HIF-lix protein by preventing its proteasomal
degradation and activating its transcriptional activity.161 We assessed whether H20
increased HIFict expression in DU145 and 22Rv1 cell lines by treating cells with
combinations of 0.25 mM H20, 50 mM PD98059 and 10 mM LY294002 for 1 hour at
37°C, followed by western blot analysis, using p-AKT, AKT, p-ERKI/2, ERKI/2 and
HIFIct specific antibodies. Interestingly, we found that HIFIct gradually increased in
DU145 cells, while its expression gradually decreased in 22Rv1 cells, both in a
concentration-dependent manner (Figure 17 A). We further correlated ROS-mediated
induction ofHlFlct with expression of p-AKT or p-ERK in DU145 cells. Increased
expression ofHIFlct was due to AKT, as abrogation of AKT expression by the inhibitor
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Figure 17: H20 differentially regulated CXCR4 and HlFlo in DU145 and 22Rv1
cells. Western blot showing increase of (A) CXCR4 and (B) HIF I x expression
DU145 but not in 22Rv1 cells. (C) Expression of p-AKT, AKT, p-ERKI/2, ERKI/2
and HiFla in DU145 cells treated with combinations of H20, PD98059 and









4.2.4 H1F1ci Promoted CXCR4 Expression in DU145 in an 11202 Dependent
Manner.
An analysis of the promoter region of CXCR4 revealed a HIFIu binding element
136 Studies have confirmed that HIFlci induces expression of CXCR4 by directly
interacting with the HRE (Hypoxia-response element) within the promoter region of
CXCR4. We wanted to investigate the correlative expression of CXCR4 and HIF I ci
upon H2O treatment. DU145 cells were treated in combinations of 0.25 mM H20, 100
mM CoCI2 and 10 mM NAC for 1 hour., which induces the accumulation ofl-lIFlci.’62
Total protein was analyzed for CXCR4 and H1F1ci expression by western blot analysis
using specific antibodies. We observed that H20 and CoCI2each induced expression of
HIF i ci, which correlated with CXCR4 expression, and was abrogated by NAC (Figure
18A). To validate that HiFici induces CXCR4 expression upon H20treatment, Cells
were transfected with HIFIci specific siRNA or scramble-siRNA using
Lipofectamine2000 to knocked down HIFIa expression (Figure 18 B). Upon HiFict
knock down we observed a concomitant decrease in CXCR4 expression, indicating that
HIF1ci regulates CXCR4 expression (Figure 18 C). Taken together, these studies indicate















Figure 18: H20induced CXCR4 expression in a 1-liFlu dependent manner in
DU145 cells. (A) CXCR4 and HIFIcL expression in cells were treated with
combinations ofH20,CoCI2 and NAC showing that CXCR4 expression is
dependent on l-IIFIcL. (B) Clone selection of cells knocked down with HIFlci
siRNA. (C) Expression of HIFIcL and CXCR4 expression in knocked down
HIFIu cells, shown that CXCR4 expression is dependent on HIFIa.
Hu + + - +
- + +
+






4.2.5 H20Promoted Apoptosis in 22Rv1 Cells But Not in DU14S Cells.
Reactive oxygen species have differential roles in prostate tumors. An
overwhelming concentration of chemotherapeutic agents, designed to increase ROS in
tumors, results in cellular apoptosis.115’163, 164 However, ROS and oxidative stress have
long been associated with tumor cell survival and metastasis.102’165, 166 We observed a
decrease in HIF1u and no change in CXCR4 expression in 22RvI cells (Figure 19 A),
two pathways that are involved in cell survival. Therefore, we determined whether
22Rv1 cells may be undergoing apoptosis. To accomplished this, cells were treated with
0.25mM H20 for 4 hours and light micrographs were taken at 20X magnification using a
Zeiss Axiovert 200M microscope (Figure 19 A). Cells were then analyzed for Annexin
V. cleaved-PARP expression by flow cytometry and western blot, respectively. Our
investigation showed that 22Rv1 cells were phenotypically smaller, condensed and
granular in the presence of H2O,compared to untreated control (Figure 1 9A), which is
indicative of apoptosis.167 Further, the cells appeared to change from a mesenchymal to
epithelial phenotype (Figure 19 A), which was not observed in DU145 cells. We
confirmed apoptosis in 22Rv1 cells by an Annexin V assay. Forty seven percent of
H2O-treated 22Rv1 cells were positive for apoptosis, compared to 19.9 % in untreated
cells. DU145 cells were not apoptotic in the presence ofH20compared to untreated
cells, 4.8% and 2.2%, respectively (Figure 19 B). We further substantiated apoptosis in
22Rv1 cells by analyzing for cleaved-PARP, an apoptotic marker that indicates caspase-3
activation 168 Hydrogen peroxide-treated 22Rv1 cells expressed cleaved-PARP, which
was abrogated byNAC; there was no expression in DU145 cells (Figure 19 C).
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Figure 19: H20 induced apoptosis in 22Rv1 cells. (A) Cells were treated with H20
for 4 hours and light micrographs were taken. (B) Expression of Annexin-V and (C)














4.2.6 H20Enhances Cell Migration and Invasion Through CXCR4 in DU145 Cells.
In this study we have shown that PTEN regulates CXCR4 signaling, and an
absence of PTEN permits CXCR4-mediated functions. Furthermore, we have found that
the accumulation of ROS promoted CXCR4 expression in DU145 cells. Therefore, we
wanted to evaluate the importance ofH20-mediated inactivation of PTEN, and up-
regulation of CXCR4 in various metastatic functions such as cell migration and invasion.
This was done by seeding 4x I 0 cells into the upper transwell chamber and allowed to
migrate towards various treatments in the lower chamber for 6 hours at 37°C in a 5% CO2
incubator. Five fields of each transwell insert were randomly selected and counted for
migrated cells at lox magnification using a Zeiss Axiovert 200M light microscope and
graphed. The counted cells were then graphicall7 representation of total migrated cells
(Figure 20 A). Then invasion assays was done by seeding 8x 1 ü cells into the upper
transwell chamber layered with matrigel and allowed to invade towards the indicated
treatments in the lower chamber for 24 hours at 37°C in a 5% CO2 incubator. Five fields
of each transwell insert were randomly selected and counted for invaded cells at i ox
magnification using a Zeiss Axiovert 200M light microscope. The counted cells were
then graphically representation of total invaded cells (Figure 20 B).
DU145 cells were evaluated for migration towards a combination of ligands and
inhibitors (0.25mM H2O, 10mM NAC and 10mM AMD3 100) in the lower chamber. By
transwell assay, we observed a significant increase in cells migrating towards H2O
compared to control (Figure 20 A), which was not observed with NAC or AMD3 100
(CXCR4 antagonist) in the lower chamber. Moreover, H2O failed to induce migration in
the simultaneous presence of NAC (Figure 20 A). Finally, using a CXCR4 antagonist,
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Figure 20: ROS induced expression of CXCR4 to enhance the migration and
invasion. (A) A graphical representation of total migrated cells. (B) A graphical
representation of total invaded cells. , P < 0.05.
we confirmed that ROS-mediated migration was through CXCR4. Likewise, ROS
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4.2.7 11202 Increased Snail Expression and Promoted Transendothelial Migration in
a CXCR4-dependent Manner
Hydrogen peroxide promotes invasion and migration of prostate cancer cells in
CXCR4-dependent manner.92 A typical feature of invasive cells is the transition from an
epithelial to mesenchymal phenotype, the establishment of polarity and the secretion of
matrix metalloproteinases (MMPs) to degrade extracellular proteins that keep tissues
intact. We first confirmed an invasive phenotype in DU145 cells by analyzing for the
EMT marker Snail.’69 Hydrogen peroxide increased Snail expression in a concentration
dependent manner (Figure 21 A), which correlated with expression of MMP(s) 13 and 14
mRNA (Figure 21 B).
The primary site of prostate cancer metastasis is the bone; it is well established
that CXCR4 is significantly involved in bone marrow homing of prostate tumors.’5’
Therefore, we investigated whether H20 promoted the transendothelial cell invasion and
migration ofDUl45 cells. Human bone marrow endothelial (HBME) cells were grown
to a monolayer on matrigel in the upper chamber of a Transwell plate. DU145 cells were
seeded on top of the 1-IBME cells, and allowed to invade the monolayer and matrigel, and
migrate towards 0.25mM 1-1202 in the bottom chamber of the Transwell plate)7°
Hydrogen peroxide induced a significant increase in transendothelial migration of
DU145 cells, compared to control (Figure 21 C), which was abrogated by NAC.
Furthermore, the migration occurred in a CXCR4-dependent manner, which was further
abrogated by AMD3 100, a CXCR4 antagonist in the lower chamber. Moreover, H20
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Figure 21: H20 induced EMT and transendothelial migration ofDUl45
cells in a CXCR4-dependent manner. (A) The expression of Snail showing
that H20 induces its expression. (B) The mRNA expression of MMP 13 and
14 in cells treated with H20 showing an induction of their expression. (C)









The notion that PTEN may regulate CXCR4-mediated function was observed in
Jurkat cells.’7’ Furthermore, prostate cancer specimens showed a correlation between
PTEN loss and CXCR4-mediated metastasis. However, these reports failed to investigate
the relationship between PTEN and CXCR4 in cancer cells. Therefore, we investigated
the correlation between PTEN loss and CXCR4 in prostate cancer cells. We were able to
show:
(1) PTEN-null PC3 cells exhibited potent CXCR4-mediated migration, indicating
that PTEN was not essential for the movement of prostate cancer cells.
(2) By transient transfection, we found that reconstitution of PTEN expression in
PC3 cells induced morphological changes and downregulated CXCR4-
mediated migration and proliferation.
(3) PTEN reconstitution regulated phospho-ERKI/2, but not phospho-AKT in
CXCR4-mediated functions. This was further supported by the observation
that MAPK inhibitors mimicked PTEN’s effect of negatively regulating
CXCR4-mediated migration.
(4) Expression of PTEN did not affect cell surface expression of CXCR4,
suggesting that inhibition of CXCR4-rnediated migration and proliferation
was at the level of signaling.
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(5) Down-regulation of wild type PTEN by siRNA in DU145 cells increased
CXCR4-mediated migration.
Collectively, these findings indicate that loss of PTEN expression iii prostate
cancer cells provides the loss of a critical inhibitory function in the signal cascade(s) that
lead to cell migration, and may provide the permissive switch to CXCR4-mediated
tumorigenesis and advanced stages of prostate cancer. Prostate cancers have the ability to
localize to tissue sites throughout the body. Loss of tumor suppressors, specific
chemoattractants and migration-promoting signaling pathways may influence sites of
specific distant tumor formation. The long-held view is that metastasis occurs by a
multistep process requiring intravasation, cell survival in the blood stream, extravasation,
initiation of micrometastasis and the establishment of new blood vessels)72 It has been
proposed that the expression, or absence, of particular genes in primary tumors may
directly predispose cancer cell growth and metastatic development. Aberrant expression
of key genes, including CXCR4 and PTEN, have been established to collectively
facilitate cell invasion, bone metastasis, cell adhesion and angiogenesis.’2’677017376
CXCR4 and PTEN are independently identified as gene expression signatures, which
reflect the activation status of oncogenic pathways, and in turn provide clinically relevant
associations with disease outcomes.’77’78
The potential prognostic role of the combined alterations in CXCR4 and PTEN in
prostate cancer is not well established. A gene expression signature for
immunohistochemistry (IHC)-detecting PTEN loss has been developed for breast cancer,
which correlates to poor patient outcome in independent data sets of breast, bladder, and
prostate carcinoma.179 Primary prostate cancers often show genetic loss or mutation of at
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least one PTEN allele in approximately 30% to 70% of advanced (locally advanced or
metastatic) cases, primarily at the level of transcription.’80’181 Conversely, in DU145,
LNCaP and PC3 prostate cancer cells, CXCR4 mRNA expression was approximately
1000, 400 and 21 times, respectively, that of primary and normal prostate cancer cell
linesl542 NPTX, Pre 2.8 and 1542 CPT3X.’82 In the same study, migration of the
metastatic cell lines PC3 and DU145 was enhanced by SDFIx ligand and inhibited by an
antibody to CXCR4, indicating that migration of metastatic prostate cancer cells was
facilitated and enhanced by the SDF1a/CXCR4 signaling axis, which did not influence
the migration of the normal prostate epithelial cells.’82 Considering the converging
pathways that CXCR4 and PTEN activate and inhibit, respectively, loss of PTEN could
provide one of the critical events in human prostate cancer that cooperates to promote
tumor development and progression through CXCR4.
There have been few studies on the role of PTEN in the metastatic events of
prostate cancer. PC3 cells transfected with wild type PTEN reverted the invasive
phenotype and invasion of collagen type jl83 Wu et al proposed that PTEN loss
upregulated cell cycle genes, cdc6 and cyclin E2, which in turn led to metastatic
colonization at distant sites.177 In defining a relationship with PTEN, Carver et al
observed that cancer specimens containing chromosomal translocations involving the
ERG locus were concomitant with the loss of PTEN expression and upregulation of
CXCR4 in prostate cancer.’84 Phillips et al reported that overexpression of wild type
PTEN in non-small cell lung cancer and other cancer mode, inhibited hypoxia-induced
CXCR4 expression.’85
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Outside of prostate cancer, one group has studied the role of PTEN and CXCR4
in the chemotactic movement of PTEN-nuIl Jurkat cells where enhanced chemotaxis was
observed.17’ Induction of PTEN expression down-regulated Jurkat cell chemotaxis
towards SDF1ct. which correlated with the reconstitution of PTEN expression.’71 In the
studies by Gao et a!, they observed that the lipid phosphatase activity of PTEN was
essential for the role of PTEN as a negative regulator of chemotaxis, suggesting that
P13K pathway was involved, and that PTEN antagonized P13K to inhibit chemotaxis.17’
In agreement with Gao et a!, we observed downregulation of CXCR4-mediated migration
and proliferation upon reconstitution of PTEN into PC3 cells.’71 We also observed an
increase in CXCR4-mediated migration of poorly migratory DU145 cells upon
downregulation of PTEN by s1RNA.
PTEN functions as a dual-functional phosphatase protein that targets lipids and
proteins. Physiologically, PIP3 is the substrate of PTEN, whereby PTEN
dephosphosphorylates PIP3, indirectly inhibiting AKT activation. We found that
phospho-ERKI/2, but not p-AKT demonstrated biphasic expression in PC3-PTEN cells
following SDFICL stimulation. We further examined the roles of the ERKI/2 and AKT
pathways in CXCR4-mediated migration by chemical impairment with PD98059 (MEK
inhibitor) and LY294002 (P13K inhibitor). PD98059 inhibited CXCR4-mediated
migration, unlike LY294002, further implicating a role for ERK1/2 in CXCR4-mediated
metastasis. Corroborating our studies, Sun et al observed that CXCR4-mediated
chondrosarcoma cell invasion was inhibited by the CXCR4 inhibitor AMD3 100, as well
as with ERKII2 inhibitor U0126 and ERKI/2 siRNA.’3° Likewise, similar results have
been demonstrated in human osteosarcoma cells 186 laryngeal and hypopharyngeal
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squamous cell carcinoma metastasis.187’188 Classically, the ERKI/2 signaling cascade is
not a target of PTEN; however, Thomas et al. reported that PTEN reconstitution in
SPARC (secreted protein acidic and rich in cysteine) suppressed the SHC-RAF-ERK
signaling pathway in SPARC-expressing cells.’89 Moreover, restoration of wildtype
PTEN induced apoptosis in Jun (+1+) cells undergoing cellular transformation by
oncogenic Ras.’9°
Taken together, metastatic signature genes (e.g. chemokine and growth factor
receptor/ligand axes) have been implicated to facilitate the cell autonomous transforming
functions of a primary disease to a malignant disease, throughout the course of tumor
progression. Since loss of PTEN activity in advanced metastatic prostate cancers leads to
increased cell proliferation, reduced cell death and metastasis, it is not implausible to
suggest that loss of PTEN activity in prostate cancer provides the permissive switch to a
CXCR4-mediated advanced metastatic disease. The loss of PTEN is a common event in
cancer and is associated with aggressive metastatic cancer, including prostate cancer
cells.’
It has been recognized that PTEN inactivation is mediated through genetic
mutation/deletion, epigenetic modification and ROS-dependent molecular modification.
Cancer cells inherently produce increasing amounts of ROS; however, other sources may
be the tumor microenvironment and immune cells. Irrespective of the source, the gradual
accumulation of ROS is commonly involved in promoting tumorigenesis through
dysregulation of various anti-cancer and pro-cancer pathways.6 ROS are an important
class of molecules that play a critical role in mediating cellular signal transduction.86
Intracellular ROS is primarily produced in mitochondrion by complexes I and III and by
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cytosolic enzymes such as NADPH oxidase (NOX,) xanthine oxidases and
cyclooxygenases.86 The continuous production of ROS leads to oxidative stress and
ultimately cell death. Conversely, low levels of ROS is involved in promoting survival
functions by inhibiting cell death and upregulating proliferation.91’2 Therefore, normal
cells maintain ROS homeostasis through various antioxidant mechanisms, such as the
glutathione and thioredoxin systems.9°The dysregulation of ROS homeostasis is
associated with development and progression of several cancer models including prostate
cancer. Typically, ROS-induction of survival pathways result in a decrease in cell death
pathway. For instance, in lymphoma cells, resveratrol induced ROS generation, which
resulted in decreased p-AKT expression, but enhanced apoptosis.191 However, Kumar et
al. showed that ROS generation activated survival pathways such as PI3K!AKT.
Together, these studies suggest that ROS plays a dual role in cell survival and
proliferation. Herein, we also describe a differential role for ROS on the survival
mechanisms of prostate cancer cells.
It is well established that ROS generation activates signaling pathways such as
PI3K/AKT and ERKI/2 pathways. We initially observed that, ROS induced expression
of p-AKT and p-ERK in both DU145 and 22Rv1 cells, which were consistent with
previously published results.6’92 The tumor suppressor PTEN has been shown to
negatively regulate the PI3K/AKT and ERK1/2 pathways; hence, loss of PTEN is
correlated with tumor development and progression of various cancer models. In the
majority of cancer cells, loss of PTEN is due to genetic mutations and epigenetic
modification; further, ROS-mediated inactivation is also an established mechanism to
abrogate the functions of PTEN by creating a disulfide bridge within the catalytic domain
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of PTEN, thereby rendering it inactive.192 Studies done by Ha et al. showed that ROS
accumulation inactivated PTEN catalytic function and promoted p-AKT expression in
hepatocellular carcinoma.193 Here, we observed that ROS oxidized the catalytic domain
of PTEN, thereby reducing its phosphatase activity; and its ineffectiveness on the
expression levels of PTEN. Collectively, our results suggest that the increased
expression of p-AKT and p-ERKI/2 observed may have been due to the inactivation of
PTEN catalytic domain by ROS. It has been recognized that mutational inactivation of
PTEN is associated with metastatic prostate cancer; however, only 63% of metastatic
tissues show loss of PTEN.194 Considering that ROS inactivates PTEN function, it is
plausible to suggest that metastatic cells expressing wild type PTEN may in fact be
inactivated through ROS generation.
The expression of CXCR4 in prostate cancer cells plays a critical role in
promoting cell survival, proliferation, invasion and migration. Notably, the expression of
HIF I ci. has been shown to increase CXCR4 expression through direct interaction with the
a I-IRE found on the promoter region.27 Previous studies have demonstrated that ROS
accumulation induced the expression of CXCR4 in mesenchymal stem cells, which
depended on l-IIFIcL accumulation.’34 The stimulation of EGF Receptor was shown to
promote the expression of CXCR4 through p-AKT mediated activation of I-hF I u in non
small cell lung cancer.’95 Additionally, the same study also showed that the
reconstitution of wild type PTEN resulted in a decrease in CXCR4 expression; suggesting
that loss of PTEN permits CXCR4 expression through p-AKT mediated induction of
HIFIUL.195 In this study, we observed an induction of CXCR4 expression by ROS in
DU145 cell line, while CXCR4 expression was unchanged in 22RvI cells. Upon
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investigation, the expression level ofHlFlcL in DU145 cells treated with ROS was
increased, but HIF1a expression steadily deceased in 22Rv1 cells. Together, these results
suggest a correlation between CXCR4 and H1FIa expression in DU145 cells; which may
be dependent on ROS-mediated induction of p-AKT.
In prostate cancer cells, the stabilization and subsequent accumulation ofHIFlcL is
generally dependent on a result of hypoxia, activation of signaling pathways and/or ROS
generation. ROS has been shown to stabilize HIFIcL accumLilation through direct
interaction, inhibition of its proteasomal degradation and kinase activation such as AKT
and ERKI/2.’43 Through inhibitor studies, we showed that the ROS-dependent
accumulation of 1-liFlu in DUI45 cells were dependent on the expression of p-AKT and
not p-ERKI/2. These observation are consistent with previously published studies;
however, studies have also shown that H1F1a expression is also dependent on the
expression p-ERKI/2.’96 Taken together our study suggests that ROS inactivation of
PTEN permits the expression and p-AKT and consequently H1FIu, thereby inducing the
expression of CXCR4 in DU145 cells. Inducing 1-liFlu with CoCI2also stimulated the
expression of CXCR4 while siRNA knocking down ofHlFla prevented its expression in
DUI45 cells; thus, confirming that increased HIF1o promoted CXCR4 expression.
Collectively, these findings imply that ROS-mediated induction of p-AKT expression
may enhance CXCR4 expression by promoting the accumulation ofHlFlct in DU145, but
not in 22RvI cells. Interestingly, upon further investigation we observed that, ROS
induced apoptosis in 22Rv1 cells, but not in DU145 cells.
We observed an increase of CXCR4 and HIFIu in DU145 cells but not in 22Rv1
cells, while apoptosis was increased in 22Rv1 but not in DU145 cells; thus, indicating
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that ROS plays a differential role in regulating cellular functions. Previous studies also
showed that ROS differentially regulated interleukin-8 and ICAM-1 in endothelial and
epithelial cells.’97 Indeed, these cells are of varying molecular and genetic background,
which may explain the differential response to ROS accumulation. It has been
established that tumor mass consists of a heterogeneous population of cells, which also
consist of a varying molecular and genetic makeup; hence, suggesting that tumor cells
may also respond differentially to various levels of ROS, whether induced or removed by
therapeutic agents. Notably, ROS concurrent induction of survival pathway and
apoptosis in 22Rvl cells further suggests a differential role of ROS at the molecular
level. It is unclear whether, ROS independent of survival pathways activate apoptosis, or
whether ROS-mediated activation of survival pathways induces apoptosis. These studies
further suggests that ROS may play a differential role on prostate cancer cells, which may
be context dependent. Furthermore, one explanation for this discrepancy may be due to
the difference in the molecular and genetic makeup of DU145 and 22Rv1 cells.
Furthermore, considering the heterogeneity of tumor tissues, it is plausible to suggest that
current oxidative treatment may solicit a response opposite to what is anticipated.
The expression of CXCR4 is significantly associated with promoting several
metastatic events including cell invasion, migration and cell survival. We have
previously shown that exogenous ROS enhanced DU145 cells migration and invasion in
CXCR4-dependent manner. In the present study, we corroborated these observations by
analyzing for the expression of EMT markers such as snail, MMPI3 and 14. We
observed that ROS induced expression of snail, MMPI3 and 14 in DUI45 cells. In
prostate cancer cells, the expression of CXCR4 is involved in promoting the bone
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specific metastasis; hence, we investigated whether ROS-mediated induction of CXCR4
is involved in promoting the bone marrow transendothelial invasion of prostate cancer
cells. We observed that DU145 cell transendothelial invasion were enhanced in the
presence H20,in a CXCR4-dependent manner.
Taken together, our results suggests that exogenous ROS differentially regulates
various cellular mechanisms responsible for cell survival and death. Drugs, such as
anthracyclines and epipodophyllotoxins, are used to induce ROS accumulation in cancer
cells hoping to create oxidative stress and induce cell death.’4’ Conversely, the
accumulation of ROS has been shown to activate survival pathways in cancer cells.’42
Our findings in prostate cancer, along with immune studies, demonstrated that ROS may
act as an inducing molecule, resulting in increased CXCR4 expression and subsequent
cell survival mechanisms. Therefore, cells may increase ROS generation and expression
of survival genes, like CXCR4, to escape oxidative stress and avoid death.’98 Based on
these observation, we speculate that treating heterogeneous tumors with oxidative therapy
intended to induce apoptosis may unintentionally induce cell survival activities; however,
additional studies are warranted to fully make this conclusion.
CHAPTER 6
CONCLUSION
The inactivation of PTEN and increased expression of CXCR4 are commonly
observed in metastatic prostate cancer, suggesting that loss of PTEN is associated with
CXCR4 expression In this study, we have demonstrated that loss of PTEN in advanced
prostate cancer cells permit CXCR4-mediated metastatic function which supported our
first hypothesis. PTEN-null PC3 cells exhibited potent CXCR4-mediated migration,
indicating that PTEN was not essential for the movement of prostate cancer cells. By
transient transfection, we found that reconstitution of PTEN expression in PC3 cells
induced morphological changes and downregulated CXCR4-mediated migration and
proliferation. PTEN reconstitution regulated phospho-ERKI/2, but not phospho-AKT in
CXCR4-mediated functions. This was further supported by the observation that MAPK
inhibitors mimicked PTEN’s effect of negatively regulating CXCR4-mediated migration.
Expression of PTEN did not affect cell surface expression of CXCR4, suggesting that
inhibition of CXCR4-mediated migration and proliferation was at the level of signaling;
and downregulation of wild type PTEN by siRNA in DU145 cells increased CXCR4-
mediated migration. Collectively, these findings indicate that loss of PTEN expression in
prostate cancer cells provides the loss of a critical inhibitory function in the signal
cascade(s) that leads to cell migration, and may provide the permissive switch to
CXCR4-mediate tumorigenesis and advanced stages of prostate cancer.
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The inactivation of PTEN is generally facilitated by genetic or epigenetic
modifications which is an early event in prostate carcinogenesis, and is correlated with
progress ion to an aggressive castration-resistant disease. Remarkably, studies have
shown, independently, that ROS inactivates PTEN and up-regulates CXCR4; therefore,
we investigated ROS-mediated PTEN inactivation, and subsequent upregulation of
CXCR4 in prostate tumorigenesis and metastasis. We observed that ROS increased
expression of p-AKT and p-ERKI/2, while PTEN expression was stabilized. The
increased expression of p-AKT and p-ERKI/2 was due to ROS-mediated inhibition of
PTEN catalytic function, which supported our second hypothesis (Figure 22). Upon
treating prostate cancer cells with ROS, we observed an upregulation of CXCR4 and
HiFict expression. We confirmed that the increase of HIFict is involved in promoting
CXCR4 expression. Furthermore, HIF I a induction was dependent on the activation of
AKT and not ERKI/2; suggesting that ROS-mediated induction of CXCR4 is through
AKT/HIF I a pathway, which supported our third hypothesis. Conversely, we observed
no induction of CXCR4 by ROS and a gradual decrease of HIF Ia expression in 22Rv 1
cells. Upon further investigation we found that ROS promoted apoptosis in 22Rv1 cells;
suggesting that in less metastatic cells are more sensitive to ROS accumulation.
However, in DU145 cells, ROS enhanced cell migration, invasion and transendothelial
invasion which depended on CXCR4. Moreover, up-regulation of CXCR4 and
subsequent functions were independent of its ligand, SDF1u.
Our results contributed to the decipherment of molecular mechanisms that exist
between the tumor microenvironment, and the imbalance of tumor suppressor and
oncogenic functions. Our studies suggests that the accumulation of ROS inactivates
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PTEN function, which then allows the PI3K/AKT pathway to activate HIF ict (Figure 22).
The increase ofl-IlFict then translocate to the nucleus and induce the expression of
CXCR4 (Figure 22).
This study adds to the body of knowledge on the role of PTEN in CXCR4-
mediated cancer progression, and hopefully, will contribute to the development of
therapies that target the tumor microenvironment, which have great potential for the
better management of metastatic prostate cancer. Understanding the relationship between
PTEN and CXCR4 will lead to new treatment options, especially for aggressive,
androgen-insensitive cancers that express low or diminished levels of PTEN and high
U
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Figure 22: A schematic showing ROS-mediated regulation of CXCR4
expression in prostate cancer cells, which is supported by this study.
I3K
AKT
levels of CXCR4. Thus, when hormone therapy is no longer an option, antagonists
against CXCR4, PI3K/AKT and/or MAPK signaling could prove to be beneficial in
regulating tumor progression once PTEN expression and function is lost.
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